

Giuseppe Curigliano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8033883/publications.pdf>

Version: 2024-02-01

735
papers

42,166
citations

4388

86
h-index

3579

181
g-index

768
all docs

768
docs citations

768
times ranked

39039
citing authors

#	ARTICLE	IF	CITATIONS
1	Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. <i>European Heart Journal</i> , 2022, 43, 280-299.	2.2	213
2	Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 95-105.	7.0	24
3	Seroconversion rate after vaccination against COVID-19 in patients with cancer—a systematic review. <i>Annals of Oncology</i> , 2022, 33, 158-168.	1.2	59
4	Advances and controversies in management of breast ductal carcinoma in situ (DCIS). <i>European Journal of Surgical Oncology</i> , 2022, 48, 736-741.	1.0	10
5	Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 165-182.	329.8	132
6	Therapeutic vaccines for breast cancer: Has the time finally come?. <i>European Journal of Cancer</i> , 2022, 160, 150-174.	2.8	49
7	Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe. <i>Journal of Personalized Medicine</i> , 2022, 12, 72.	2.5	26
8	Targeting brain metastases in breast cancer. <i>Cancer Treatment Reviews</i> , 2022, 103, 102324.	7.7	46
9	Immuno-oncology trends: preclinical models, biomarkers, and clinical development. , 2022, 10, e003231.		20
10	Aiming at a Tailored Cure for ERBB2-Positive Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2022, 8, 629.	7.1	18
11	Health-related quality of life in older patients with HER2+ metastatic breast cancer: Comparing pertuzumab plus trastuzumab with or without metronomic chemotherapy in a randomised open-label phase II clinical trial. <i>Journal of Geriatric Oncology</i> , 2022, 13, 582-593.	1.0	4
12	Efficacy of targeted therapies for oncogene-driven lung cancer in early single-arm versus late phase randomized clinical trials: A comparative analysis. <i>Cancer Treatment Reviews</i> , 2022, 104, 102354.	7.7	2
13	Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. , 2022, 10, e004001.		45
14	Evolution of low HER2 expression between early and advanced-stage breast cancer. <i>European Journal of Cancer</i> , 2022, 163, 35-43.	2.8	88
15	Global challenges and policy solutions in breast cancer control. <i>Cancer Treatment Reviews</i> , 2022, 104, 102339.	7.7	74
16	Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 465-484.	2.5	6
17	Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?. <i>Annals of Oncology</i> , 2022, 33, 234-238.	1.2	11
18	Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. <i>Annals of Oncology</i> , 2022, 33, 321-329.	1.2	97

#	ARTICLE	IF	CITATIONS
19	ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. <i>Annals of Oncology</i> , 2022, 33, 466-487.	1.2	67
20	Immunotherapy for early triple negative breast cancer: research agenda for the next decade. <i>Npj Breast Cancer</i> , 2022, 8, 23.	5.2	67
21	Abstract PD8-01: Phase 3 SOPHIA study of margetuximab (M) + chemotherapy (CTX) vs trastuzumab (T) + CTX in patients (pts) with HER2+ metastatic breast cancer (MBC) after prior anti-HER2 therapies: Final overall survival (OS) analysis. <i>Cancer Research</i> , 2022, 82, PD8-01-PD8-01.	0.9	4
22	Abstract GS3-03: Genomic analysis of 733 HER2+ breast cancers identifies recurrent pathways alterations associated with anti-HER2 resistance and new therapeutic vulnerabilities. <i>Cancer Research</i> , 2022, 82, GS3-03-GS3-03.	0.9	0
23	Abstract P4-06-08: Consensus on the utility of breast cancer multigene signatures in routine clinical practice among European breast cancer specialists - 1st results of the PROCURE project. <i>Cancer Research</i> , 2022, 82, P4-06-08-P4-06-08.	0.9	0
24	Abstract OT1-02-02: A global, phase 2 study of ARX788 in patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens. <i>Cancer Research</i> , 2022, 82, OT1-02-02-OT1-02-02.	0.9	0
25	Differences in the Molecular Profile between Primary Breast Carcinomas and Their Cutaneous Metastases. <i>Cancers</i> , 2022, 14, 1151.	3.7	5
26	Abstract P2-13-04: Final survival analysis of a phase 3 study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2-positive early or locally advanced breast cancer. <i>Cancer Research</i> , 2022, 82, P2-13-04-P2-13-04.	0.9	2
27	First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 499-514.	2.3	7
28	Bystander effect of antibody-drug conjugates: fact or fiction?. <i>Current Oncology Reports</i> , 2022, 24, 809-817.	4.0	35
29	Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 1143-1154.	27.0	474
30	HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 834651.	3.5	63
31	CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 593-605.	4.1	31
32	Cyclin dependent kinase 4/6 inhibitors in early breast cancer: what is the role of Ki-67?. <i>Lancet Oncology</i> , The, 2022, 23, 325-328.	10.7	1
33	Evaluation of the TCR Repertoire as a Predictive and Prognostic Biomarker in Cancer: Diversity or Clonality?. <i>Cancers</i> , 2022, 14, 1771.	3.7	15
34	How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed?. <i>ESMO Open</i> , 2022, 7, 100428.	4.5	4
35	SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis. <i>European Journal of Cancer</i> , 2022, 166, 202-207.	2.8	4
36	Harmonizing PD-L1 testing in metastatic triple negative breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 345-348.	3.1	10

#	ARTICLE	IF	CITATIONS
37	Understanding resistance to immune checkpoint inhibitors in advanced breast cancer. Expert Review of Anticancer Therapy, 2022, 22, 141-153.	2.4	5
38	Single-Cells Isolation and Molecular Analysis: Focus on HER2-Low CTCs in Metastatic Breast Cancer. Cancers, 2022, 14, 79.	3.7	7
39	Definition of High-Risk Early Hormone-Positive HER2~Negative Breast Cancer: A Consensus Review. Cancers, 2022, 14, 1898.	3.7	20
40	Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives. Cancer Treatment Reviews, 2022, 106, 102395.	7.7	60
41	Clinical and pathological features of breast cancer patients eligible for adjuvant abemaciclib. Annals of Oncology, 2022, 33, 845-847.	1.2	5
42	Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification. Annals of Oncology, 2022, 33, 702-712.	1.2	24
43	Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression. Breast, 2022, 64, 100-111.	2.2	5
44	Emerging treatment landscape of non-muscle invasive bladder cancer. Expert Opinion on Biological Therapy, 2022, 22, 717-734.	3.1	8
45	Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Moving Into a New Era. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 82-92.	3.8	6
46	Heart toxicity effects (HTE) of anthracyclines-containing regimens (ACRs) in patients with breast cancer (BC) carrying mutational signature of homologous recombination deficiency (HRD).. Journal of Clinical Oncology, 2022, 40, 10519-10519.	1.6	0
47	Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03.. Journal of Clinical Oncology, 2022, 40, 1000-1000.	1.6	9
48	Targeting HER2-positive metastatic breast cancer with ARX788, a novel anti-HER2 antibody-drug conjugate in patients whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens.. Journal of Clinical Oncology, 2022, 40, TPS1112-TPS1112.	1.6	0
49	Quantifying geographical accessibility to cancer clinical trials in different income landscapes. ESMO Open, 2022, 7, 100515.	4.5	3
50	Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents.. Journal of Clinical Oncology, 2022, 40, 3063-3063.	1.6	0
51	Clinical activity of <sc>CCâ€90011</sc>, an oral, potent, and reversible <sc>LSD1</sc> inhibitor, in advanced malignancies. Cancer, 2022, 128, 3185-3195.	4.1	10
52	Consensus on the utility of breast cancer multigene signatures in routine clinical practice: Results of the PROCURE Project.. Journal of Clinical Oncology, 2022, 40, e13639-e13639.	1.6	0
53	Challenges and Obstacles in Applying Therapeutical Indications Formulated in Molecular Tumor Boards. Cancers, 2022, 14, 3193.	3.7	9
54	Efficacy and safety of dostarlimab in patients (pts) with mismatch repair deficient (dMMR) solid tumors: Analysis of 2 cohorts in the GARNET study.. Journal of Clinical Oncology, 2022, 40, 2587-2587.	1.6	6

#	ARTICLE	IF	CITATIONS
55	Safety and efficacy results from the expansion phase of the first-in-human study evaluating TGF β 2 inhibitor SAR439459 alone and combined with cemiplimab in adults with advanced solid tumors.. Journal of Clinical Oncology, 2022, 40, 2524-2524.	1.6	3
56	Pralsetinib in patients (pts) with advanced or metastatic <i>RET</i> -altered thyroid cancer (TC): Updated data from the ARROW trial.. Journal of Clinical Oncology, 2022, 40, 6080-6080.	1.6	5
57	Molecular landscape and actionable alterations in a genomic-guided cancer clinical trial: First analysis of the ROME trial.. Journal of Clinical Oncology, 2022, 40, 3087-3087.	1.6	2
58	Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?. Expert Opinion on Investigational Drugs, 2022, 31, 855-874.	4.1	2
59	Rethinking breast cancer follow-up based on individual risk and recurrence management. Cancer Treatment Reviews, 2022, 109, 102434.	7.7	14
60	Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe?. European Journal of Cancer, 2022, 171, 25-42.	2.8	9
61	Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: Initial experience from a Compassionate Use Program in Italy. European Journal of Cancer, 2022, 172, 332-339.	2.8	6
62	Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma. Clinical Cancer Research, 2021, 27, 438-446.	7.0	21
63	Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188487.	7.4	16
64	Margetuximab for the treatment of HER2-positive metastatic breast cancer. Expert Opinion on Biological Therapy, 2021, 21, 127-133.	3.1	21
65	CDK4/6 inhibitors for HR+HER2 ⁺ early stage breast cancer – when to escalate treatment?. Nature Reviews Clinical Oncology, 2021, 18, 67-68.	27.6	4
66	ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research. Annals of Oncology, 2021, 32, 337-350.	1.2	76
67	Pathological and clinical features of enteric adenocarcinoma of the thymus. A pooled analysis of cases from a reference center and systematic review of the literature. Cancer Treatment Reviews, 2021, 92, 102133.	7.7	4
68	Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2. Annals of Oncology, 2021, 32, 113-119.	1.2	51
69	New anti-HER2 agents for brain metastasis: histology-agnostic weapons?. Breast Cancer Research and Treatment, 2021, 185, 879-881.	2.5	3
70	Development of a cure model for the estimation of long-term outcomes in patients with microsatellite instability(MSI)-high metastatic colorectal cancer (mCRC) receiving immune-checkpoint inhibitors (ICIs).. Journal of Clinical Oncology, 2021, 39, 87-87.	1.6	0
71	Adjuvant and Neoadjuvant Treatment of Triple-Negative Breast Cancer With Chemotherapy. Cancer Journal (Sudbury, Mass), 2021, 27, 41-49.	2.0	26
72	Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox. Lancet Oncology, The, 2021, 22, e18-e28.	10.7	49

#	ARTICLE	IF	CITATIONS
73	Clinical development and current role of margetuximab for the treatment of breast cancer. <i>Drugs of Today</i> , 2021, 57, 551.	1.1	3
74	Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9-9.	1.6	69
75	The Global Landscape of Treatment Standards for Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1143-1155.	6.3	13
76	Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion-positive solid tumors.. <i>Journal of Clinical Oncology</i> , 2021, 39, 467-467.	1.6	16
77	Antibody-drug conjugates in solid tumors: a look into novel targets. <i>Journal of Hematology and Oncology</i> , 2021, 14, 20.	17.0	129
78	Abstract PS2-11: Ctc-her2+ a novel subset in stage IV aggressive: Molecular correlations, outcome and clinical characteristics in metastatic breast cancer. <i>Cancer Research</i> , 2021, 81, PS2-11-PS2-11.	0.9	3
79	Bringing Onco-Innovation to Europe's Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine. <i>Cancers</i> , 2021, 13, 583.	3.7	13
80	Activity of novel anti-HER2 agents for breast cancer based on hormone receptors expression. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 885-886.	2.5	3
81	Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. <i>JCO Global Oncology</i> , 2021, 7, 162-172.	1.8	38
82	Abstract PS2-15: The HER2 circulating ratio to define HER2 expressing circulating tumor cells in advanced breast cancer. <i>Cancer Research</i> , 2021, 81, PS2-15-PS2-15.	0.9	2
83	Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TReND trial. <i>Breast Cancer Research</i> , 2021, 23, 38.	5.0	14
84	PIK3CA Mutation Assessment in HR+/HER2- Metastatic Breast Cancer: Overview for Oncology Clinical Practice. <i>Journal of Molecular Pathology</i> , 2021, 2, 42-54.	1.2	9
85	The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality. <i>Cancer Treatment Reviews</i> , 2021, 94, 102169.	7.7	14
86	Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis. <i>European Journal of Cancer</i> , 2021, 145, 197-209.	2.8	16
87	Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 159, 103223.	4.4	52
88	Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET). <i>Clinical Cancer Research</i> , 2021, 27, 3443-3455.	7.0	4
89	Updated results from phase I study of CC-90011 in patients (pts) with solid tumours (STs), including neuroendocrine neoplasms (NENs), and relapsed/refractory non-Hodgkin lymphoma (R/R NHL). <i>Annals of Oncology</i> , 2021, 32, S4.	1.2	0
90	COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 313-319.	27.6	103

#	ARTICLE	IF	CITATIONS
91	Accelerating progress from advanced to early breast cancer for TNBC. <i>Breast</i> , 2021, 56, S10.	2.2	0
92	Commentary: SARS-CoV-2 vaccines and cancer patients. <i>Annals of Oncology</i> , 2021, 32, 569-571.	1.2	43
93	Phase I/Ib Clinical Trial of Sabatolimab, an Anti- TIM-3 Antibody, Alone and in Combination with Spatalizumab, an Anti- PD-1 Antibody, in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 3620-3629.	7.0	151
94	Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. , 2021, 9, e002501.		18
95	Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 573.	7.1	217
96	Strategies to overcome resistance to immune checkpoint blockade in lung cancer. <i>Lung Cancer</i> , 2021, 154, 151-160.	2.0	25
97	SARS-CoV-2 vaccines for cancer patients: a call to action. <i>European Journal of Cancer</i> , 2021, 148, 316-327.	2.8	55
98	Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer: a systematic review. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 323-337.	2.5	15
99	Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability-high tumors: A combined analysis of two cohorts in the GARNET study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2564-2564.	1.6	25
100	26P Characterization of low HER2 expressions in de-novo metastatic breast cancer. <i>Annals of Oncology</i> , 2021, 32, S31.	1.2	1
101	A phase 1/2 open-label study of KY1044, an anti-ICOS antibody with dual mechanism of action, as single agent and in combination with atezolizumab, in adult patients with advanced malignancies.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2624-2624.	1.6	10
102	Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase 3 trial. <i>European Journal of Cancer</i> , 2021, 148, 382-394.	2.8	22
103	24P Consensus on the utility of breast cancer multigene signatures in routine clinical practice among European breast cancer clinicians: The PROCURE project. <i>Annals of Oncology</i> , 2021, 32, S30-S31.	1.2	0
104	8P Mutational analysis of circulating tumour DNA (ctDNA) in patients with ER+/HER2- advanced breast cancer (ABC) receiving palbociclib (P): Results from the TReEnd trial. <i>Annals of Oncology</i> , 2021, 32, S24.	1.2	0
105	Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation. <i>Lung Cancer</i> , 2021, 155, 127-135.	2.0	6
106	Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB).. <i>Journal of Clinical Oncology</i> , 2021, 39, 1043-1043.	1.6	9
107	Breast cancer. <i>Lancet, The</i> , 2021, 397, 1750-1769.	13.7	731
108	Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer. <i>European Journal of Cancer</i> , 2021, 148, 134-145.	2.8	10

#	ARTICLE	IF	CITATIONS
109	Chest wall infiltration is a critical prognostic factor in breast implant-associated anaplastic large-cell lymphoma affected patients. <i>European Journal of Cancer</i> , 2021, 148, 277-286.	2.8	7
110	Safety and efficacy of pralsetinib in patients with advanced <i>RET</i> fusion-positive non-small cell lung cancer: Update from the ARROW trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9089-9089.	1.6	9
111	SGNTGT-001: A phase 1 study of SEA-TGT, an effector-function enhanced monoclonal antibody (mAb), in advanced malignancies (trial in progress).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS2657-TPS2657.	1.6	4
112	KY1044 to target the ICOS pathways inducing intratumoral Treg depletion and agonism of effector T cells: Preliminary pharmacodynamic markers from a phase 1/2 multicenter trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2626-2626.	1.6	0
113	Clinical activity and safety of the RET inhibitor pralsetinib in patients with <i>RET</i> fusion-positive solid tumors: Update from the ARROW trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3079-3079.	1.6	6
114	Correlation between different levels of HER2 expression in circulating tumor cells (cHER2 ratio) and metastatic behavior in stageIV _{aggressive} breast cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3036-3036.	1.6	3
115	Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021, 149, 134-152.	2.8	41
116	Adherence to COVID-19 vaccines in cancer patients: promote it and make it happen!. <i>European Journal of Cancer</i> , 2021, 153, 257-259.	2.8	12
117	Antibody-Drug Conjugates for the Treatment of Breast Cancer. <i>Cancers</i> , 2021, 13, 2898.	3.7	34
118	Managing side effects of immune checkpoint inhibitors in breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 162, 103354.	4.4	15
119	COVID-19 vaccines in patients with cancer. <i>Lancet Oncology</i> , The, 2021, 22, 738-739.	10.7	16
120	Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial. <i>ESMO Open</i> , 2021, 6, 100106.	4.5	9
121	Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring. <i>ESMO Open</i> , 2021, 6, 100117.	4.5	37
122	The global landscape of drug development of trastuzumab biosimilars. <i>Journal of Cancer Policy</i> , 2021, 28, 100273.	1.4	3
123	Benefit of adjuvant chemotherapy in patients with lobular breast cancer: A systematic review of the literature and metanalysis. <i>Cancer Treatment Reviews</i> , 2021, 97, 102205.	7.7	21
124	The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2021, 150, 155-167.	2.8	45
125	Emerging issues related to COVID-19 vaccination in patients with cancer. <i>Oncology and Therapy</i> , 2021, , 1-11.	2.6	15
126	The global landscape of availability, accessibility and affordability of essential diagnostics and therapeutics for the management of HER2-positive breast cancer: The ONCOLLEGE-001 survey. <i>Journal of Cancer Policy</i> , 2021, 28, 100285.	1.4	9

#	ARTICLE	IF	CITATIONS
127	Mastering the Use of Novel Anti-HER2 Treatment Options. JCO Oncology Practice, 2021, 17, 605-606.	2.9	6
128	Association of Breast Cancer Irradiation With Cardiac Toxic Effects. JAMA Oncology, 2021, 7, 924.	7.1	17
129	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. Cancer Discovery, 2021, 11, 2796-2811.	9.4	79
130	Assessing population diversity in phase III trials of cancer drugs supporting Food and Drug Administration approval in solid tumors. International Journal of Cancer, 2021, 149, 1455-1462.	5.1	16
131	SY16-1 Advances in early breast cancer (EBC) care from the perspective of escalation and de-escalation. Annals of Oncology, 2021, 32, S260.	1.2	0
132	SO-9 Analysis of the immune-related endpoints of the mismatch repair-deficient non-endometrial solid cancers cohort from the GARNET study. Annals of Oncology, 2021, 32, S205-S206.	1.2	0
133	Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncology, The, 2021, 22, 959-969.	10.7	222
134	Precision medicine in breast cancer: From clinical trials to clinical practice. Cancer Treatment Reviews, 2021, 98, 102223.	7.7	34
135	Alpelisib in combination with everolimus±Aexemestane in solid tumours: Phase Ib randomised, open-label, multicentre study. European Journal of Cancer, 2021, 151, 49-62.	2.8	19
136	Thymic carcinoma with Lynch syndrome or microsatellite instability, a rare entity responsive to immunotherapy. European Journal of Cancer, 2021, 153, 162-167.	2.8	10
137	Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. Annals of Oncology, 2021, 32, 1496-1510.	1.2	42
138	Complex Differential Diagnosis between Primary Breast Cancer and Breast Metastasis from EGFR-Mutated Lung Adenocarcinoma: Case Report and Literature Review. Current Oncology, 2021, 28, 3384-3392.	2.2	4
139	Anthracyclines for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Are We Ready to Let Them Go?. Journal of Clinical Oncology, 2021, 39, 3541-3545.	1.6	6
140	Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. , 2021, 9, e003370.		10
141	Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes and Endocrinology,the, 2021, 9, 491-501.	11.4	192
142	Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMBtrial). European Journal of Cancer, 2021, 153, 223-233.	2.8	9
143	Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies. Pharmaceuticals, 2021, 14, 884.	3.8	17
144	A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degradar, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer. Clinical Cancer Research, 2021, 27, 5760-5770.	7.0	25

#	ARTICLE	IF	CITATIONS
145	First line treatment of BRAF mutated advanced melanoma: Does one size fit all?. Cancer Treatment Reviews, 2021, 99, 102253.	7.7	26
146	1583P COVID-19 related risk in patients enrolled in early-phase clinical trials. Annals of Oncology, 2021, 32, S1140-S1141.	1.2	0
147	Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development. Expert Opinion on Investigational Drugs, 2021, , 1-15.	4.1	8
148	The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer. European Journal of Cancer, 2021, 154, 175-189.	2.8	24
149	Should temozolomide be used on the basis of O6-methylguanine DNA methyltransferase status in patients with advanced neuroendocrine tumors? A systematic review and meta-analysis. Cancer Treatment Reviews, 2021, 99, 102261.	7.7	7
150	A Phase 1&2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC. Journal of Thoracic Oncology, 2021, 16, 1559-1569.	1.1	41
151	LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study. Annals of Oncology, 2021, 32, S1287-S1288.	1.2	64
152	Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. Cancers, 2021, 13, 4421.	3.7	12
153	266P MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC): Safety and efficacy results from the ongoing phase Ib study (B-PRECISE-01). Annals of Oncology, 2021, 32, S478-S479.	1.2	2
154	94P ESCAT ranking of genomic alterations collected in the Italian Registry of Actionable Mutations. Annals of Oncology, 2021, 32, S397.	1.2	0
155	Biomedical omics: first insights of a new MSc degree of the University of Milan. Tumori, 2021, , 030089162110472.	1.1	1
156	558TiP Phase I study of effector-function enhanced monoclonal antibody (mAb), SEA-TGT, in advanced malignancies. Annals of Oncology, 2021, 32, S615-S616.	1.2	0
157	991P Treatment-related adverse events (TRAEs) occurring during dostarlimab therapy in the GARNET study. Annals of Oncology, 2021, 32, S845-S846.	1.2	0
158	Therapeutic cancer vaccines revamping: technology advancements and pitfalls. Annals of Oncology, 2021, 32, 1537-1551.	1.2	36
159	Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions. Expert Review of Clinical Pharmacology, 2021, 14, 1233-1252.	3.1	14
160	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Annals of Oncology, 2021, 32, 1216-1235.	1.2	354
161	Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology. ESMO Open, 2021, 6, 100237.	4.5	10
162	Fed or fasted state for oral therapies in breast cancer treatment? A comprehensive review of clinical practice recommendations. Cancer Treatment Reviews, 2021, 100, 102281.	7.7	4

#	ARTICLE	IF	CITATIONS
163	Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials. European Journal of Cancer, 2021, 157, 40-49.	2.8	3
164	Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates. JAMA Oncology, 2021, 7, 1873.	7.1	66
165	National health system characteristics, breast cancer stage at diagnosis, and breast cancer mortality: a population-based analysis. Lancet Oncology, The, 2021, 22, 1632-1642.	10.7	84
166	Clinical, Pathological, and Molecular Features of Breast Carcinoma Cutaneous Metastasis. Cancers, 2021, 13, 5416.	3.7	7
167	Precision Cancer Medicine: Large Studies Indicate Steady Progress. Cancer Discovery, 2021, 11, 2677-2678.	9.4	6
168	ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Annals of Oncology, 2021, 32, 1475-1495.	1.2	454
169	Distribution of the workforce involved in cancer care: a systematic review of the literature. ESMO Open, 2021, 6, 100292.	4.5	18
170	370â€¦Time course of treatment-related adverse events (TRAEs) during dostarlimab therapy in the GARNET trial. , 2021, 9, A398-A398.		0
171	Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1. , 2021, 9, e003224.		12
172	Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials. Cancers, 2021, 13, 5829.	3.7	8
173	Novel immune targets for the treatment of triple-negative breast cancer. Expert Opinion on Therapeutic Targets, 2021, 25, 815-834.	3.4	11
174	Pan-Asian adaptation of the EHNSâ€¦ESMOâ€¦ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck. ESMO Open, 2021, 6, 100309.	4.5	29
175	Accelerating progress in early triple-negative breast cancer: A viewpoint on antibody-drug conjugates, back from St Gallen breast cancer conference 2021. Breast, 2021, , .	2.2	1
176	Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptorâ€¦Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors. JAMA Oncology, 2020, 6, 100.	7.1	68
177	Expression of tumor-associated antigens in breast cancer subtypes. Breast, 2020, 49, 202-209.	2.2	24
178	CDK4/6 inhibitors in breast cancer: one more step towards reduced mortality. Lancet Oncology, The, 2020, 21, 191-192.	10.7	7
179	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. New England Journal of Medicine, 2020, 382, 597-609.	27.0	789
180	18O CC-90011 in patients (Pts) with advanced solid tumors (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL): Updated results of a phase I study. Annals of Oncology, 2020, 31, S6.	1.2	1

#	ARTICLE	IF	CITATIONS
181	137O Tucatinib vs placebo added to trastuzumab and capecitabine in previously treated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB). Annals of Oncology, 2020, 31, S62-S63.	1.2	0
182	Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents. European Journal of Cancer, 2020, 139, 92-98.	2.8	12
183	Repurposing anticancer drugs for the management of COVID-19. European Journal of Cancer, 2020, 141, 40-61.	2.8	59
184	Impact of the COVID-19 Pandemic on Cancer Care: A Global Collaborative Study. JCO Global Oncology, 2020, 6, 1428-1438.	1.8	189
185	Delivering Cancer Care During the COVID-19 Pandemic: Recommendations and Lessons Learned From ASCO Global Webinars. JCO Global Oncology, 2020, 6, 1461-1471.	1.8	44
186	171P An outcomes summary of the clinical advances curriculum on CDK4 & 6 inhibition in breast cancer. Annals of Oncology, 2020, 31, S77.	1.2	2
187	6P Circulating tumour cells (CTCs) as biomarkers of resistance to the CDK4/6 inhibitor (CDK4/6i) palbociclib (P) in patients (pts) with ER+/HER2-negative advanced breast cancer (ABC). Annals of Oncology, 2020, 31, S18.	1.2	0
188	Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. Npj Breast Cancer, 2020, 6, 54.	5.2	181
189	How to treat lobular cancer in the adjuvant setting?. Current Opinion in Oncology, 2020, 32, 561-567.	2.4	5
190	5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 2020, 31, 1623-1649.	1.2	761
191	36P Eligibility and outcomes in phase I clinical trials testing targeted therapy, immunotherapy and combinations: A single-institution study. Annals of Oncology, 2020, 31, S13.	1.2	0
192	5P Association between baseline tumor size and outcome in patients treated with next-generation immunoncology agents. Annals of Oncology, 2020, 31, S1-S2.	1.2	0
193	1913O Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC). Annals of Oncology, 2020, 31, S1084.	1.2	29
194	LBA1 Interim results of a phase I/Ib study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib (RIB) or alpelisib (ALP) in patients with ER+ breast cancer (BC) who had progressed after endocrine therapy (ET). Annals of Oncology, 2020, 31, S62.	1.2	9
195	Progresses Toward Precision Medicine in RET-altered Solid Tumors. Clinical Cancer Research, 2020, 26, 6102-6111.	7.0	39
196	Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicity. European Journal of Cancer, 2020, 141, 218-224.	2.8	8
197	Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis. Journal of Translational Medicine, 2020, 18, 446.	4.4	1
198	Use of chemotherapy in elderly patients with early-stage triple-negative breast cancer. Lancet Oncology, The, 2020, 21, 1543-1545.	10.7	4

#	ARTICLE	IF	CITATIONS
199	Atezolizumab and Bevacizumab in Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2020, 383, 693-695.	27.0	16
200	Clinical features affecting survival in metastatic NSCLC treated with immunotherapy: A critical review of published data. <i>Cancer Treatment Reviews</i> , 2020, 89, 102085.	7.7	41
201	Cancer Patients and Risk of Mortality for COVID-19. <i>Cancer Cell</i> , 2020, 38, 161-163.	16.8	47
202	Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. <i>Annals of Oncology</i> , 2020, 31, 1320-1335.	1.2	219
203	Antibody-drug conjugates in breast cancer: the chemotherapy of the future?. <i>Current Opinion in Oncology</i> , 2020, 32, 494-502.	2.4	25
204	P-79 C-PRECISE-01 study: A phase Ib/II trial of MEN1611, a PI3K inhibitor, and cetuximab in patients with PIK3CA mutated metastatic colorectal cancer failing irinotecan, oxaliplatin, 5-FU and anti-EGFR containing regimens. <i>Annals of Oncology</i> , 2020, 31, S115.	1.2	3
205	The legacy of Professor Aron Goldhirsch. <i>Annals of Oncology</i> , 2020, 31, 671-673.	1.2	0
206	A role for the immune system in advanced laryngeal cancer. <i>Scientific Reports</i> , 2020, 10, 18327.	3.3	14
207	Adjuvant treatment of early male breast cancer. <i>Current Opinion in Oncology</i> , 2020, 32, 594-602.	2.4	6
208	ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer. <i>ESMO Open</i> , 2020, 5, e000793.	4.5	113
209	187P Impact of oncotype DX on agreement and confidence in adjuvant treatment decision making in breast cancer. <i>Annals of Oncology</i> , 2020, 31, S317-S318.	1.2	0
210	275O Impact of tucatinib on health-related quality of life (HRQoL) in patients with HER2+ metastatic breast cancer (MBC) with and without brain metastases (BM). <i>Annals of Oncology</i> , 2020, 31, S349-S350.	1.2	4
211	298P Differences in the mutational profile between primary breast carcinomas and their cutaneous metastasis. <i>Annals of Oncology</i> , 2020, 31, S362.	1.2	0
212	339P Impact of blood glucose levels on the efficacy of everolimus-exemestane in patients with advanced HR-positive/HER2 negative breast cancer: The EVERMET study. <i>Annals of Oncology</i> , 2020, 31, S382-S383.	1.2	0
213	Cellular immunotherapy in breast cancer: The quest for consistent biomarkers. <i>Cancer Treatment Reviews</i> , 2020, 90, 102089.	7.7	27
214	Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies. <i>European Journal of Cancer</i> , 2020, 139, 43-50.	2.8	267
215	Pretreatment Blood Parameters Predict Efficacy from Immunotherapy Agents in Early Phase Clinical Trials. <i>Oncologist</i> , 2020, 25, e1732-e1742.	3.7	16
216	Management of Cardiac Toxicity Induced by Chemotherapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 2885.	2.4	24

#	ARTICLE	IF	CITATIONS
217	Cardio-Oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 480-504.	329.8	29
218	Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. <i>Lancet Oncology</i> , The, 2020, 21, 1234-1243.	10.7	297
219	Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours. <i>ESMO Open</i> , 2020, 5, e001081.	4.5	6
220	Implementing clinical practice guidelines: time to assess it. <i>ESMO Open</i> , 2020, 5, e001130.	4.5	0
221	1074TIP SGNTGT-001: A phase I study of SGN-TGT, an effector-function enhanced monoclonal antibody (mAb), in advanced malignancies. <i>Annals of Oncology</i> , 2020, 31, S729-S730.	1.2	0
222	LBA76_PR Expected medium and long term impact of the COVID-19 outbreak in oncology. <i>Annals of Oncology</i> , 2020, 31, S1205-S1206.	1.2	6
223	LBA77 Anti-SARS-CoV-2 antibody response in patients with cancer and oncology healthcare workers: A multicenter, prospective study. <i>Annals of Oncology</i> , 2020, 31, S1206.	1.2	5
224	300P Association between the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios and efficacy of CDK 4/6 inhibitors in advanced breast cancer: The observational multicenter Italian PALMARES study. <i>Annals of Oncology</i> , 2020, 31, S362-S363.	1.2	2
225	528O CC-90011 in patients (Pts) with advanced solid tumours (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL): Updated results of a phase I study. <i>Annals of Oncology</i> , 2020, 31, S464.	1.2	0
226	442P Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC). <i>Annals of Oncology</i> , 2020, 31, S1413-S1414.	1.2	2
227	Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a 2-drug cocktail in patients with MET dysregulated advanced solid tumours: A phase I, multicentre, open-label, single-sequence drug-drug interaction study. <i>British Journal of Clinical Pharmacology</i> , 2020, 87, 2867-2878.	2.4	8
228	Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms. <i>JCO Global Oncology</i> , 2020, 6, 1357-1362.	1.8	16
229	Bringing Greater Accuracy to Europe's Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology. <i>Biomedicine Hub</i> , 2020, 5, 1-42.	1.2	15
230	Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS ONE trial. <i>ESC Heart Failure</i> , 2020, 7, 1452-1466.	3.1	16
231	Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden. <i>Oncologist</i> , 2020, 25, 803-809.	3.7	26
232	Risk of coronavirus disease 2019 in patients treated for cancer: An immune response-based hypothesis. <i>European Journal of Cancer</i> , 2020, 134, 6-8.	2.8	1
233	51P Evolution of low HER2 expressions between primary and metastatic breast cancer. <i>Annals of Oncology</i> , 2020, 31, S33.	1.2	1
234	134TIP A phase III trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2- primary breast cancer: CheckMate 7FL. <i>Annals of Oncology</i> , 2020, 31, S60-S61.	1.2	2

#	ARTICLE	IF	CITATIONS
235	151P The landscape of patients with metastatic breast cancer enrolled in phase I trials. <i>Annals of Oncology</i> , 2020, 31, S70-S71.	1.2	0
236	In Reply. <i>Oncologist</i> , 2020, 25, e1252-e1253.	3.7	0
237	Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response. , 2020, 8, e000617.		57
238	Synergistic effect of fasting-mimicking diet and vitamin C against KRAS mutated cancers. <i>Nature Communications</i> , 2020, 11, 2332.	12.8	90
239	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 17.	5.2	106
240	Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 2610-2619.	1.6	331
241	Evolution of Cancer Care in Response to the COVID-19 Pandemic. <i>Oncologist</i> , 2020, 25, e1426-e1427.	3.7	7
242	Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy. <i>British Journal of Cancer</i> , 2020, 123, 694-697.	6.4	37
243	Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019. <i>European Journal of Cancer</i> , 2020, 135, 62-65.	2.8	32
244	Modified-BEP Chemotherapy in Patients With Germ-Cell Tumors Treated at a Comprehensive Cancer Center. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 381-387.	1.3	3
245	Pharmacological management of male breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1493-1504.	1.8	3
246	A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group. <i>Oncologist</i> , 2020, 25, e936-e945.	3.7	520
247	Tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 347-354.	2.5	59
248	The global landscape of drug development for kidney cancer. <i>Cancer Treatment Reviews</i> , 2020, 89, 102061.	7.7	5
249	Theoretical and practical knowledge curriculum for European Breast Surgeons. <i>European Journal of Surgical Oncology</i> , 2020, 46, 717-736.	1.0	12
250	Moving beyond endocrine therapy for luminal metastatic breast cancer in the precision medicine era: looking for new targets. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 7-22.	0.7	5
251	Enhancing global access to cancer medicines. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 105-124.	329.8	123
252	Is Explanation a Marketing Problem? The Quest for Trust in Artificial Intelligence and Two Conflicting Solutions. <i>Public Health Genomics</i> , 2020, 23, 2-5.	1.0	11

#	ARTICLE	IF	CITATIONS
253	Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars. <i>Journal of Clinical Oncology</i> , 2020, 38, 1070-1080.	1.6	19
254	Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. <i>Annals of Oncology</i> , 2020, 31, 171-190.	1.2	582
255	Breast implant-associated anaplastic large cell lymphoma: A comprehensive review. <i>Cancer Treatment Reviews</i> , 2020, 84, 101963.	7.7	61
256	Tumour infiltrating lymphocytes and correlation with response to intensified platinum-based chemotherapy in BRCA-like tumours. <i>European Journal of Cancer</i> , 2020, 127, 236-239.	2.8	3
257	Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TReND Trial. <i>Clinical Cancer Research</i> , 2020, 26, 2131-2139.	7.0	40
258	The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy Region. <i>European Journal of Cancer</i> , 2020, 132, 199-206.	2.8	48
259	Breast implant-associated anaplastic large cell lymphoma: emotional impact and guidelines for psychological support. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 221-224.	2.5	7
260	ESOâ€ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4). <i>Annals of Oncology</i> , 2020, 31, 674-696.	1.2	172
261	Biologic therapy for advanced breast cancer: recent advances and future directions. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1009-1024.	3.1	23
262	Master protocols in immuno-oncology: do novel drugs deserve novel designs?. , 2020, 8, e000475.		17
263	HER2-Low Breast Cancer: Pathological and Clinical Landscape. <i>Journal of Clinical Oncology</i> , 2020, 38, 1951-1962.	1.6	353
264	Effect of the COVID-19 pandemic on cancer treatment and research. <i>Lancet Haematology</i> , the, 2020, 7, e432-e435.	4.6	103
265	Recommendations for triage, prioritization and treatment of breast cancer patients during the COVID-19 pandemic. <i>Breast</i> , 2020, 52, 8-16.	2.2	188
266	Conducting phase 1 cancer clinical trials during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)â€related disease pandemic. <i>European Journal of Cancer</i> , 2020, 132, 8-10.	2.8	12
267	How can biosimilars change the trajectory of breast cancer therapy?. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 325-328.	2.4	12
268	Lucitanib for the Treatment of HR+/HER2â~ Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study. <i>Clinical Cancer Research</i> , 2020, 26, 354-363.	7.0	40
269	How to Guarantee the Best of Care to Patients with Cancer During the COVID-19 Epidemic: The Italian Experience. <i>Oncologist</i> , 2020, 25, 463-467.	3.7	33
270	Escalating and De-escalating Therapy for Early-Stage HER2-Positive Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 3-13.	3.8	8

#	ARTICLE	IF	CITATIONS
271	1678P_PR The impact of COVID-19 pandemic on cancer care: A global collaborative study. <i>Annals of Oncology</i> , 2020, 31, S1209-S1210.	1.2	5
272	Abstract GS1-01: Tucatinib vs placebo, both combined with capecitabine and trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases (HER2CLIMB). , 2020, , .		2
273	Abstract GS1-02: Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis. <i>Cancer Research</i> , 2020, 80, GS1-02-GS1-02.	0.9	24
274	Abstract P3-09-03: A phase II study of pembrolizumab and eribulin in patients with HR-positive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes (KELLY study). , 2020, , .		1
275	Abstract PD7-09: A phase 1/1b study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib in patients with estrogen receptor-positive (ER+) advanced breast cancer (ABC) who had progressed after endocrine therapy (ET). , 2020, , .		2
276	A phase I dose escalation study evaluating the safety and tolerability of a novel anti-HER2 antibody-drug conjugate (PF-06804103) in patients with HER2-positive solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1039-1039.	1.6	26
277	SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) + Ctx versus trastuzumab (T) + Ctx in patients (pts) with pretreated HER2+ metastatic (met) breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 1040-1040.	1.6	2
278	Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 109-109.	1.6	49
279	Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9515-9515.	1.6	57
280	First-line durvalumab + monalizumab, mFOLFOX6, and bevacizumab or cetuximab for metastatic microsatellite-stable colorectal cancer (MSS-CRC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 128-128.	1.6	6
281	Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair deficient (dMMR) GI cancers.. <i>Journal of Clinical Oncology</i> , 2020, 38, 218-218.	1.6	5
282	Combinations using checkpoint blockade to overcome resistance. <i>Ecancermedalscience</i> , 2020, 14, 1148.	1.1	11
283	Abstract P4-10-07: Tumor ER protein modulation, molecular characterization and monitoring of cfDNA in phase 1 study of LSZ102 and LSZ102 + ribociclib in patients with ER+ MBC. , 2020, , .		0
284	Abstract 2488: Characterization of gene fusions in paired primary and metastatic samples of breast cancer in the AURORA molecular screening program. , 2020, , .		0
285	Abstract OT2-04-03: Nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2- primary breast cancer: CheckMate 7FL. , 2020, , .		1
286	Abstract P1-18-04: Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: Infusion time substudy results. , 2020, , .		0
287	Estimating Mortality in Patients with Hematological Malignancy and COVID-19: A Pooled Analysis of 10 Studies. <i>Blood</i> , 2020, 136, 13-14.	1.4	0
288	Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. <i>Annals of Oncology</i> , 2019, 30, 1541-1557.	1.2	464

#	ARTICLE	IF	CITATIONS
289	Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer. <i>European Journal of Cancer</i> , 2019, 118, 41-48.	2.8	48
290	Biosimilars for breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1015-1021.	3.1	4
291	Prognostic value of tumour infiltrating lymphocytes (TILs) in patients with early-stage triple negative breast cancers (TNBC) in the absence of chemotherapy. <i>Annals of Oncology</i> , 2019, 30, v55.	1.2	3
292	Treatment with BLU-667, a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and thyroid cancer. <i>Annals of Oncology</i> , 2019, 30, v790.	1.2	3
293	Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside. <i>European Journal of Cancer</i> , 2019, 122, 22-41.	2.8	7
294	Clinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22. <i>Annals of Oncology</i> , 2019, 30, v365.	1.2	7
295	Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	3.0	11
296	European Guidelines on the Organisation of Breast Centres and Voluntary Certification Processes. <i>Breast Care</i> , 2019, 14, 359-365.	1.4	4
297	What therapies are on the horizon for HER2 positive breast cancer?. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 811-822.	2.4	3
298	Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-“positive breast cancer. <i>European Journal of Cancer</i> , 2019, 120, 1-9.	2.8	39
299	Are all cyclin-dependent kinases 4/6 inhibitors created equal?. <i>Npj Breast Cancer</i> , 2019, 5, 27.	5.2	85
300	Evaluating triptorelin as a treatment option for breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1809-1818.	1.8	3
301	Are Biosimilars the Future of Oncology and Haematology?. <i>Drugs</i> , 2019, 79, 1609-1624.	10.9	10
302	Safety of Novel Targeted Therapies in Oncology. <i>Drug Safety</i> , 2019, 42, 157-158.	3.2	1
303	EUSOMA position regarding breast implant associated anaplastic large cell lymphoma (BIA-ALCL) and the use of textured implants. <i>Breast</i> , 2019, 44, 90-93.	2.2	25
304	Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors. <i>Cancer Treatment Reviews</i> , 2019, 74, 21-28.	7.7	31
305	Secondary mechanisms of anti-HER2 resistance in breast cancer: NF1 as an actionable target. <i>Annals of Oncology</i> , 2019, 30, iii6-iii7.	1.2	1
306	Development of Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and Chemotherapy-Resistant Breast Cancer PDXs. <i>Cells</i> , 2019, 8, 605.	4.1	12

#	ARTICLE	IF	CITATIONS
307	Treatment in real-life patients with HER2-positive metastatic breast cancer: What we learn from the KAMILLA trial?. European Journal of Cancer, 2019, 117, 1-4.	2.8	2
308	The evolving landscape of “next-generation” immune checkpoint inhibitors: A review. European Journal of Cancer, 2019, 117, 14-31.	2.8	74
309	Systemic Impact of Breast Reconstruction. , 2019, , 769-774.		0
310	Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TReEnd trial. Breast Cancer Research, 2019, 21, 71.	5.0	19
311	An analysis of available biomarker data for targeting cyclin-dependent kinases 4 and 6 (CDK4/6) in breast cancer. Expert Review of Precision Medicine and Drug Development, 2019, 4, 129-138.	0.7	1
312	Recent advances in triple negative breast cancer: the immunotherapy era. BMC Medicine, 2019, 17, 90.	5.5	267
313	Combination of Hypoglycemia and Metformin Impairs Tumor Metabolic Plasticity and Growth by Modulating the PP2A-GSK3 β -MCL-1 Axis. Cancer Cell, 2019, 35, 798-815.e5.	16.8	212
314	Defining the immunogram of breast cancer: a focus on clinical trials. Expert Opinion on Biological Therapy, 2019, 19, 383-385.	3.1	14
315	Safety, Tolerability, and Management of Toxic Effects of Phosphatidylinositol 3-Kinase Inhibitor Treatment in Patients With Cancer. JAMA Oncology, 2019, 5, 1347.	7.1	56
316	T-cell bispecific antibodies to bypass MHC class I loss in breast cancer. Annals of Oncology, 2019, 30, 877-879.	1.2	9
317	Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Annals of Oncology, 2019, 30, 766-773.	1.2	78
318	Peptide vaccines in early breast cancer. Breast, 2019, 44, 128-134.	2.2	12
319	Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b “2 trial. Lancet Oncology, The, 2019, 20, 371-382.	10.7	327
320	Homologous recombination deficiency in triple negative breast cancer. Breast, 2019, 45, 15-21.	2.2	58
321	WDR5 inhibition halts metastasis dissemination by repressing the mesenchymal phenotype of breast cancer cells. Breast Cancer Research, 2019, 21, 123.	5.0	31
322	Breast Cancer: Reimbursement Policies and Adoption of New Therapeutic Agents by National Health Systems. Breast Care, 2019, 14, 373-381.	1.4	8
323	Prevention, Monitoring, and Management of Cardiac Dysfunction in Patients with Metastatic Breast Cancer. Oncologist, 2019, 24, e1034-e1043.	3.7	13
324	TRIPLE NEGATIVE ADVANCED BREAST CANCER: BIOLOGY AND RESISTANCE. Breast, 2019, 48, S25.	2.2	0

#	ARTICLE	IF	CITATIONS
325	Editorial: Optimizing treatment strategy in early breast cancer: less is more, or more is better?. Current Opinion in Oncology, 2019, 31, 469-471.	2.4	1
326	RADIOFREQUENCY ABLATION FOR LIVER METASTASES IN THE TREATMENT OF ADVANCED BREAST CANCER. Breast, 2019, 48, S74.	2.2	0
327	Harmonizing gene signatures to predict benefit from adjuvant chemotherapy in early breast cancer. Current Opinion in Oncology, 2019, 31, 472-479.	2.4	3
328	Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. Annals of Oncology, 2019, 30, 1941-1949.	1.2	155
329	Treatment with pralsetinib (formerly BLU-667), a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC). Annals of Oncology, 2019, 30, ix122.	1.2	13
330	Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy. Annals of Oncology, 2019, 30, 236-242.	1.2	123
331	A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer. Expert Review of Clinical Pharmacology, 2019, 12, 9-16.	3.1	4
332	Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Annals of Oncology, 2019, 30, 397-404.	1.2	538
333	Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life. Critical Reviews in Oncology/Hematology, 2019, 133, 171-182.	4.4	93
334	Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology. Drug Safety, 2019, 42, 247-262.	3.2	66
335	Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in youngBRCA-mutated breast cancer patients. Reproductive BioMedicine Online, 2019, 38, 835-844.	2.4	29
336	The role of histone deacetylase inhibitors in metastatic breast cancer. Breast, 2019, 43, 130-134.	2.2	42
337	Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer. Advances in Experimental Medicine and Biology, 2019, 1168, 9-30.	1.6	114
338	Abstract B057: BMS-986148, an anti-mesothelin antibody-drug conjugate (ADC), alone or in combination with nivolumab demonstrates clinical activity in patients with select advanced solid tumors. Molecular Cancer Therapeutics, 2019, 18, B057-B057.	4.1	13
339	Abstract CT183: Phase (Ph) I/II study of MBG453± spartalizumab (PDR001) in patients (pts) with advanced malignancies. Cancer Research, 2019, 79, CT183-CT183.	0.9	29
340	Abstract OT1-03-01: Phase 1/1b study of novel oral selective estrogen receptor degrader (SERD) LSZ102 in combination with alpelisib (BYL719) in estrogen receptor-positive (ER+), human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer (ABC) with progression on endocrine therapy (ET). Cancer Research, 2019, 79, OT1-03-01-OT1-03-01.	0.9	2
341	SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).. Journal of Clinical Oncology, 2019, 37, 1000-1000.	1.6	71
342	FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis.. Journal of Clinical Oncology, 2019, 37, 4511-4511.	1.6	45

#	ARTICLE	IF	CITATIONS
343	Evaluation of survival by ADCC status: Subgroup analysis of SB3 (Trastuzumab Biosimilar) and reference trastuzumab in patients with HER2-positive early breast cancer at three-year follow-up.. Journal of Clinical Oncology, 2019, 37, 580-580.	1.6	3
344	Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers.. Journal of Clinical Oncology, 2019, 37, 6018-6018.	1.6	34
345	Ph1/2 study of Rova-T in combination with nivolumab (Nivo) ± ipilimumab (Ipi) for patients (pts) with 2L+ extensive-stage (ED) SCLC.. Journal of Clinical Oncology, 2019, 37, 8516-8516.	1.6	9
346	Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2019, 37, 9008-9008.	1.6	75
347	Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with <i>BRAF</i> V600E mutated biliary tract cancer (BTC): A cohort of the ROAR basket trial.. Journal of Clinical Oncology, 2019, 37, 187-187.	1.6	66
348	BMS-986205, an indoleamine 2, 3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (nivo): Updated safety across all tumor cohorts and efficacy in advanced bladder cancer (advBC).. Journal of Clinical Oncology, 2019, 37, 358-358.	1.6	37
349	Opportunities and challenges of implementing Pharmacogenomics in cancer drug development. , 2019, 2, 43-52.		4
350	Abstract P2-08-11: Tumor infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer. , 2019, , .		0
351	Abstract PD1-08: Phase 1/1b study of novel oral selective estrogen receptor degrader (SERD) LSZ102 for estrogen receptor-positive (ER+) advanced breast cancer (ABC) with progression on endocrine therapy (ET). , 2019, , .		1
352	Abstract P6-17-09: Event-free survival by ADCC status from a follow-up study comparing SB3 (trastuzumab biosimilar) with reference trastuzumab for HER2 positive breast cancer in neoadjuvant setting. , 2019, , .		2
353	Abstract 4416: Plasma thymidine kinase activity in patients with luminal metastatic breast cancer treated with Palbociclib within the phase II TReND trial. , 2019, , .		0
354	Toward precision medicine in inflammatory breast cancer. Translational Cancer Research, 2019, 8, S469-S478.	1.0	4
355	Targeting the microenvironment in solid tumors. Cancer Treatment Reviews, 2018, 65, 22-32.	7.7	342
356	Addition of platinum salts to neoadjuvant chemotherapy in triple-negative breast cancer: a new standard of care?. Lancet Oncology, The, 2018, 19, 434-436.	10.7	3
357	A new approach to assess drug sensitivity in cells for novel drug discovery. Expert Opinion on Drug Discovery, 2018, 13, 339-346.	5.0	6
358	Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. Lancet Oncology, The, 2018, 19, 323-336.	10.7	94
359	Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer. Expert Opinion on Pharmacotherapy, 2018, 19, 299-305.	1.8	4
360	Adjuvant Chemotherapy. , 2018, , 439-445.		0

#	ARTICLE	IF	CITATIONS
361	The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTO. European Journal of Cancer, 2018, 89, 42-48.	2.8	13
362	Reply to "The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology" by Kirova et al.. Annals of Oncology, 2018, 29, 281-282.	1.2	3
363	Cetuximab for treating non-small cell lung cancer. Expert Opinion on Biological Therapy, 2018, 18, 483-493.	3.1	44
364	Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one Trial. European Journal of Cancer, 2018, 94, 126-137.	2.8	163
365	A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer. Annals of Oncology, 2018, 29, 162-169.	1.2	46
366	Comparing granulocyte colony-stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients. European Journal of Cancer, 2018, 89, 49-55.	2.8	18
367	Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey. ESMO Open, 2018, 3, e000422.	4.5	50
368	Combination of the S49076 with gefitinib in NSCLC patients progressing on EGFR-TKI and harboring MET/AXL dysregulation. Annals of Oncology, 2018, 29, viii525.	1.2	3
369	Physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in BRCA-mutated breast cancer (BC) patients (pts): Results from the BCY3/BCC 2017 survey. Annals of Oncology, 2018, 29, viii606.	1.2	0
370	Precision Trial Drawer, a Computational Tool to Assist Planning of Genomics-Driven Trials in Oncology. JCO Precision Oncology, 2018, 2, 1-16.	3.0	2
371	Cancer Evolution as the New Frontier of Precision Medicine. Handbook of Experimental Pharmacology, 2018, 249, 289-297.	1.8	1
372	Report on the status of women occupying leadership roles in oncology. ESMO Open, 2018, 3, e000423.	4.5	35
373	Settings-based efficacy comparison of trastuzumab biosimilars in breast cancer: A systematic literature review. Annals of Oncology, 2018, 29, viii104.	1.2	2
374	Liver toxicity in the era of immune checkpoint inhibitors: A practical approach. Critical Reviews in Oncology/Hematology, 2018, 132, 125-129.	4.4	19
375	Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncology, The, 2018, 19, 1385-1393.	10.7	342
376	The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients. Breast, 2018, 42, 41-49.	2.2	75
377	Impact of neoadjuvant chemotherapy and pathological complete response on eligibility for breast-conserving surgery in patients with early breast cancer: A meta-analysis. European Journal of Cancer, 2018, 97, 1-6.	2.8	35
378	Gyneco-oncological genomics and emerging biomarkers for cancer treatment with immune-checkpoint inhibitors. Seminars in Cancer Biology, 2018, 52, 253-258.	9.6	12

#	ARTICLE	IF	CITATIONS
379	Talking to patients about biosimilars. <i>Future Oncology</i> , 2018, 14, 2403-2414.	2.4	14
380	Inflammatory breast cancer and chest wall disease: The oncologist perspective. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1142-1147.	1.0	6
381	Edoxaban for Cancer-Associated Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2018, 379, 93-96.	27.0	14
382	A rude awakening from tumour cells. <i>Nature</i> , 2018, 554, 35-36.	27.8	7
383	Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date. <i>Breast Cancer: Targets and Therapy</i> , 2018, Volume 10, 23-29.	1.8	15
384	Perspectives on preoperative systemic treatment and breast conservative surgery: One step forward or two steps back?. <i>Breast</i> , 2018, 41, 133-135.	2.2	8
385	Precision trial designer-web: A web-based app to assist in the design of genomics-driven trials. <i>Annals of Oncology</i> , 2018, 29, iii26.	1.2	0
386	4th ESOâ€ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). <i>Annals of Oncology</i> , 2018, 29, 1634-1657.	1.2	891
387	The PROMISe to increase precision in adjuvant therapy for early breast cancer: To â€œTypeâ€•or to â€œPrintâ€?. <i>Npj Breast Cancer</i> , 2018, 4, 12.	5.2	1
388	Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial. <i>Annals of Oncology</i> , 2018, 29, 1748-1754.	1.2	76
389	Abstract CT152: A phase II study of pembrolizumab and eribulin in patients with HR-positive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes (KELLY study)., 2018, , .		1
390	Abstract GS2-06: Phase Ib/II study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER2-positive metastatic breast cancer: Results from the PANACEA (IBCSG 45-13/BIG 4-13/KEYNOTE-014) study. <i>Cancer Research</i> , 2018, 78, GS2-06-GS2-06.	0.9	32
391	A phase I/II study of the oncolytic peptide LTX-315 combined with checkpoint inhibition generates de novo T-cell responses and clinical benefit in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3094-3094.	1.6	8
392	First-in-human dose escalation of monalizumab plus durvalumab, with expansion in patients with metastatic microsatellite-stable colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3540-3540.	1.6	35
393	Safety and clinical activity of durvalumab monotherapy in patients with gastroesophageal cancers.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4032-4032.	1.6	4
394	BMS-986205, an indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (NIVO): Updated safety across all tumor cohorts and efficacy in pts with advanced bladder cancer (advBC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4512-4512.	1.6	17
395	Interim results of a phase 1/2 study of JNJ-63723283, an anti-PD-1 monoclonal antibody, in patients with advanced cancers.. <i>Journal of Clinical Oncology</i> , 2018, 36, 58-58.	1.6	3
396	A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors. <i>Oncotarget</i> , 2018, 9, 31709-31718.	1.8	32

#	ARTICLE	IF	CITATIONS
397	Prognostic implications of residual disease (RD) tumor-infiltrating lymphocytes (TIL) in triple negative breast cancer (TNBC) after neo-adjuvant chemotherapy (NAC).. Journal of Clinical Oncology, 2018, 36, 571-571.	1.6	0
398	The Emerging Role of “Liquid Biopsies,” Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations. Current Oncology Reports, 2017, 19, 1.	4.0	53
399	The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials. European Journal of Cancer, 2017, 75, 245-258.	2.8	82
400	Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. Oncoimmunology, 2017, 6, e1253654.	4.6	146
401	Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study. Breast Cancer Research and Treatment, 2017, 162, 479-488.	2.5	14
402	Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 575-581.	3.3	17
403	Breast Cancer Cardio-Oncology. , 2017, , 241-252.		0
404	Treatment of Hypertension in Patients Receiving Cancer Therapy. , 2017, , 105-123.		2
405	3rd ESO“ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Annals of Oncology, 2017, 28, 16-33.	1.2	865
406	Dual HER2 inhibition and pathological complete response in early breast cancer: increasing success of treatment by improving patient selection. Annals of Oncology, 2017, 28, 441-443.	1.2	8
407	Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial. Breast, 2017, 34, 89-95.	2.2	15
408	SAFE trial: an ongoing randomized clinical study to assess the role of cardiotoxicity prevention in breast cancer patients treated with anthracyclines with or without trastuzumab. Medical Oncology, 2017, 34, 75.	2.5	23
409	Identification of genetic determinants of breast cancer immunogenicity. Breast, 2017, 32, S1.	2.2	0
410	3rd ESO“ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). Breast, 2017, 31, 244-259.	2.2	171
411	The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast. Annals of Oncology, 2017, 28, 321-328.	1.2	72
412	Evaluation of inter-observer variability according to RECIST 1.1 and its influence on response classification in CT measurement of liver metastases. European Journal of Radiology, 2017, 95, 96-101.	2.6	7
413	Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 527-537.	7.4	59
414	Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies. European Journal of Cancer, 2017, 86, 257-265.	2.8	31

#	ARTICLE	IF	CITATIONS
415	Extending indication of cyclin-dependent kinase 4/6 inhibitors in the adjuvant and neoadjuvant setting. Current Opinion in Oncology, 2017, 29, 428-433.	2.4	2
416	Notch inhibitors and their role in the treatment of triple negative breast cancer: promises and failures. Current Opinion in Oncology, 2017, 29, 411-427.	2.4	29
417	Entinostat for the treatment of breast cancer. Expert Opinion on Investigational Drugs, 2017, 26, 965-971.	4.1	54
418	Breast cancer mortality in European Union: An outlook of good news and bad news in a two-speed Europe!. Breast, 2017, 36, 86-88.	2.2	2
419	Extended Adjuvant Chemotherapy in Triple-Negative Breast Cancer. Breast Care, 2017, 12, 152-158.	1.4	14
420	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Advances in Anatomic Pathology, 2017, 24, 311-338.	4.3	530
421	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Advances in Anatomic Pathology, 2017, 24, 225-251.	4.3	469
422	How to Achieve Optimal Care in Early Breast Cancer with 'Less' or 'More' Treatment. Breast Care, 2017, 12, 136-137.	1.4	0
423	Prognostic value of tumour-infiltrating lymphocytes in small HER2-positive breast cancer. European Journal of Cancer, 2017, 87, 164-171.	2.8	7
424	Targeting Immune Checkpoint. , 2017, , 781-785.		1
425	Targeting PI3K/AKT/mTOR Pathway. , 2017, , 787-793.		0
426	Targeting Genome Instability and DNA Repair. , 2017, , 795-805.		0
427	Robotic nipple-sparing mastectomy for the treatment of breast cancer: Feasibility and safety study. Breast, 2017, 31, 51-56.	2.2	109
428	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. European Journal of Heart Failure, 2017, 19, 9-42.	7.1	920
429	Over-using chemotherapy in the adjuvant setting. Breast, 2017, 31, 303-308.	2.2	9
430	From the maximum tolerable to the minimum effective treatment: The Umberto Veronesi's life commitment to breast cancer care. Breast, 2017, 31, 241-243.	2.2	1
431	A gene signature of chemo-immunization to predict outcome in patients with triple negative breast cancer treated with anthracycline-based neoadjuvant chemotherapy. Annals of Oncology, 2017, 28, v68.	1.2	3
432	G-CSF and G-CSF Biosimilars: A Meta-Analysis of Randomized Clinical Trials in Breast Cancer Patients Undergoing Myelosuppressive Chemotherapy. Breast, 2017, 36, S69.	2.2	0

#	ARTICLE	IF	CITATIONS
433	MA 12.02 Phase I/II Study of S49076, a MET/AXL/FGFR Inhibitor, Combined with Gefitinib in NSCLC Patients Progressing on EGFR TKI. Journal of Thoracic Oncology, 2017, 12, S1847-S1848.	1.1	4
434	Efficacy and Safety of Platinum and Metronomic Cyclophosphamide in Triple Negative Breast Cancer. Breast, 2017, 36, S47.	2.2	2
435	Impact of neoadjuvant therapy (NT) and pathological complete response (pCR) on breast-conserving surgery (BCS) in patients (pts) with breast cancer (BC): A meta-analysis. Annals of Oncology, 2017, 28, v50-v51.	1.2	1
436	Prognostic value of tumor-infiltrating lymphocytes in small HER2-positive breast cancer. Annals of Oncology, 2017, 28, vi32.	1.2	0
437	Precision Trial Designer: A computational tool to assist in the design of genomics-driven trials in oncology. Annals of Oncology, 2017, 28, vii3-vii4.	1.2	0
438	Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy. BioMed Research International, 2017, 2017, 1-7.	1.9	65
439	Targeting DNA Repair. Handbook of Experimental Pharmacology, 2017, 249, 161-180.	1.8	0
440	De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Annals of Oncology, 2017, 28, 1700-1712.	1.2	844
441	Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer. Oncotarget, 2017, 8, 2320-2328.	1.8	66
442	Maximizing the Clinical Benefit of Anthracyclines in Addition to Taxanes in the Adjuvant Treatment of Early Breast Cancer. Journal of Clinical Oncology, 2017, 35, 2600-2603.	1.6	10
443	Abstract CT055: A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) (HER2CLIMB). , 2017, , .		3
444	Abstract OT1-02-07: SOPHIA: A phase 3, randomized study of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in the treatment of patients with HER2+ metastatic breast cancer. , 2017, , .		2
445	A phase II trial of the CDK4/6 inhibitor palbociclib (P) as single agent or in combination with the same endocrine therapy (ET) received prior to disease progression, in patients (pts) with hormone receptor positive (HR+) HER2 negative (HER2â”) metastatic breast cancer (mBC) (TREnd trial).. Journal of Clinical Oncology, 2017, 35, 1002-1002.	1.6	14
446	Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.. Journal of Clinical Oncology, 2017, 35, 1008-1008.	1.6	99
447	Initial efficacy of anti-lymphocyte activation gene-3 (antiâ€“LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with antiâ€“PD-1/PD-L1 therapy.. Journal of Clinical Oncology, 2017, 35, 9520-9520.	1.6	188
448	A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB).. Journal of Clinical Oncology, 2017, 35, TPS1107-TPS1107.	1.6	1
449	Chest Wall Disease: The Clinical Continuum Between Inflammatory and Lymphangitic Breast Cancer. , 2017, , 719-727.		0
450	Targeting FGFR Pathway in Breast Cancer. , 2017, , 819-822.		0

#	ARTICLE	IF	CITATIONS
451	Integrating Next-Generation Sequencing Data in Trial Design. , 2017, , 823-827.		0
452	A gene signature of chemo-immunization to predict outcome in patients with triple negative breast cancer treated with neoadjuvant chemotherapy.. Journal of Clinical Oncology, 2017, 35, 575-575.	1.6	1
453	Arrhythmias and QTc Prolongations. , 2016, , 245-269.		0
454	Highlights from the 38th SABCS annual meeting, 8th â€“ 12th December 2015, San Antonio, USA. Ecanermedalscience, 2016, 10, 618.	1.1	3
455	Agnostos precision medicine project: a multicenter clinical and translational initiative in patients (PTS) with cancer of unknown primary (CUP). Annals of Oncology, 2016, 27, iv123.	1.2	0
456	Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. Breast Cancer Research and Treatment, 2016, 158, 323-331.	2.5	100
457	Cardio-Oncology Training: A Proposal From the International Cardioncology Society and Canadian Cardiac Oncology Network for a New Multidisciplinary Specialty. Journal of Cardiac Failure, 2016, 22, 465-471.	1.7	54
458	Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer. Cancer Treatment Reviews, 2016, 50, 205-207.	7.7	50
459	Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. Ca-A Cancer Journal for Clinicians, 2016, 66, 309-325.	329.8	485
460	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. European Heart Journal, 2016, 37, 2768-2801.	2.2	1,996
461	Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond. Therapeutic Advances in Medical Oncology, 2016, 8, 360-374.	3.2	37
462	Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study. Breast, 2016, 28, 191-198.	2.2	105
463	Being more precise in assessing the value of precision medicine in breast cancer. Breast, 2016, 29, 186-187.	2.2	0
464	Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity?. European Journal of Surgical Oncology, 2016, 42, 1780-1786.	1.0	26
465	A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC). Annals of Oncology, 2016, 27, vi98.	1.2	0
466	A phase Ib dose-finding study of alpelisib (ALP; BYL719) and paclitaxel (PTX) in advanced solid tumors (aST). Annals of Oncology, 2016, 27, vi119.	1.2	1
467	Understanding cognitive processes behind acceptance or refusal of phase I trials. Critical Reviews in Oncology/Hematology, 2016, 100, 69-73.	4.4	21
468	Biosimilars: Extrapolation for oncology. Critical Reviews in Oncology/Hematology, 2016, 104, 131-137.	4.4	40

#	ARTICLE	IF	CITATIONS
469	Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies. , 2016, 157, 120-124.		86
470	A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors. Breast Cancer Research and Treatment, 2016, 156, 319-330.	2.5	25
471	A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment, 2016, 156, 301-310.	2.5	37
472	Response to Letters Regarding Article, "Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy" Circulation, 2016, 133, e363.	1.6	3
473	The influential and inspirational Gianni Bonadonna's life commitment to evidence-based cancer medicine. Annals of Oncology, 2016, 27, 6-8.	1.2	90
474	Abstract CT061: A phase Ib study of alpelisib (BYL719) + everolimus ± exemestane in patients with advanced solid tumors or HR+/HER2-breast cancer. , 2016, , .		7
475	Abstract OT1-03-03: FINESSE - An open, 3-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or non-amplified oestrogen receptor positive metastatic breast cancer. , 2016, , .		2
476	Abstract OT3-01-05: PANACEA (IBCSG 45-13/BIG 4-13): A phase Ib/II trial evaluating the efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant, HER2-positive, metastatic breast cancer. Cancer Research, 2016, 76, OT3-01-05-OT3-01-05.	0.9	6
477	Abstract P2-08-02: Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple negative breast cancer treated by induction chemotherapy with or without oral low dose cyclophosphamide-methotrexate maintenance chemotherapy (CMM). Cancer Research, 2016, 76, P2-08-02-P2-08-02.	0.9	1
478	Phase Ib study of BGJ398 in combination with BYL719 in patients (pts) with select advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, 2500-2500.	1.6	14
479	Phase I study of the PI3K/mTOR inhibitor gedatolisib (PF-05212384) in combination with docetaxel, cisplatin, and dacomitinib.. Journal of Clinical Oncology, 2016, 34, 2566-2566.	1.6	8
480	SOPHIA: A phase 3, randomized study of margetuximab (M) plus chemotherapy (CTX) vs trastuzumab (T) plus CTX in the treatment of patients with HER2+ metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2016, 34, TPS630-TPS630.	1.6	4
481	RNAi screens identify CHD4 as an essential gene in breast cancer growth. Oncotarget, 2016, 7, 80901-80915.	1.8	37
482	Impact of autoimmune diseases on outcome of patients with early breast cancer. Oncotarget, 2016, 7, 51184-51192.	1.8	10
483	Future perspectives in cancer immunotherapy. Annals of Translational Medicine, 2016, 4, 273-273.	1.7	29
484	Clonal evolution and drug resistance in the blood of patients with metastatic solid tumors responding to targeted therapies: The CORNUCOPIA study.. Journal of Clinical Oncology, 2016, 34, TPS11615-TPS11615.	1.6	0
485	Genomic analysis of circulating tumor DNA to predict endocrine resistance and clonal evolution in patients with prostate cancer: Clinical perspectives and research opportunities. Translational Cancer Research, 2016, 5, S800-S802.	1.0	0
486	HER2 Equivocal Status in Early Breast Cancer Is Not Associated with Higher Risk of Recurrence. Anticancer Research, 2016, 36, 3537-40.	1.1	1

#	ARTICLE	IF	CITATIONS
487	IN17 CAN IMMUNE-BASED THERAPIES BE THE KEY?. Breast, 2015, 24, S27.	2.2	0
488	Immune checkpoint inhibitors with radiotherapy and locoregional treatment. Current Opinion in Oncology, 2015, 27, 445-451.	2.4	39
489	Targeting fibroblast growth factor receptor pathway in breast cancer. Current Opinion in Oncology, 2015, 27, 452-456.	2.4	17
490	Lessons from the first ecancer symposium on angiogenesis in gastric cancer. Ecancermedicalsecience, 2015, 9, 553.	1.1	0
491	Immunosuppression and Multiple Primary Malignancies in Kidney-Transplanted Patients: A Single-Institute Study. BioMed Research International, 2015, 2015, 1-8.	1.9	20
492	Immunotherapy of Breast Cancer. Progress in Tumor Research, 2015, 42, 30-43.	0.1	27
493	Crosstalk between bone niche and immune system: Osteoimmunology signaling as a potential target for cancer treatment. Cancer Treatment Reviews, 2015, 41, 61-68.	7.7	48
494	Clinical considerations for the development of biosimilars in oncology. MAbs, 2015, 7, 286-293.	5.2	47
495	Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ. Annals of Oncology, 2015, 26, 682-687.	1.2	51
496	QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review. Targeted Oncology, 2015, 10, 27-43.	3.6	20
497	Surgery of the primary tumor in de novo metastatic breast cancer: To do or not to do?. European Journal of Surgical Oncology, 2015, 41, 1288-1292.	1.0	30
498	Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. Modern Pathology, 2015, 28, 1185-1201.	5.5	205
499	Highlights from the 14th St Gallen International Breast Cancer Conference 2015 in Vienna: Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer. Ecancermedicalsecience, 2015, 9, 518.	1.1	50
500	Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Annals of Oncology, 2015, 26, 1280-1291.	1.2	177
501	De-escalation attempts for adjuvant trastuzumab: longer beats shorter. Annals of Oncology, 2015, 26, 1275-1276.	1.2	0
502	Antiangiogenic therapy in recurrent breast cancer with lymphangitic spread to the chest wall: A randomized phase II trial of bevacizumab with sequential or concurrent oral vinorelbine and capecitabine. Breast, 2015, 24, 263-271.	2.2	13
503	PG 4.02 Immune pathways and immunome as a target. Breast, 2015, 24, S8.	2.2	0
504	Promising antiproliferative platinum(II) complexes based on imidazole moiety: synthesis, evaluation in HCT-116 cancer cell line and interaction with Ctr-1 Met-rich domain. Bioorganic and Medicinal Chemistry, 2015, 23, 2538-2547.	3.0	21

#	ARTICLE	IF	CITATIONS
505	Tailoring therapies“improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. <i>Annals of Oncology</i> , 2015, 26, 1533-1546.	1.2	1,449
506	Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy. <i>Circulation</i> , 2015, 131, 1981-1988.	1.6	1,179
507	New approaches for improving outcomes in breast cancer in Europe. <i>Breast</i> , 2015, 24, 321-330.	2.2	42
508	Neoadjuvant Model for Testing Emerging Targeted Therapies in Breast Cancer. <i>Journal of the National Cancer Institute Monographs</i> , 2015, 2015, 51-55.	2.1	8
509	Mechanisms of anorexia“cachexia syndrome and rational for treatment with selective ghrelin receptor agonist. <i>Cancer Treatment Reviews</i> , 2015, 41, 793-797.	7.7	27
510	Outcome of Immediate Breast Reconstruction in Patients With Nonendocrine-Responsive Breast Cancer: A Monoinstitutional Case-Control Study. <i>Clinical Breast Cancer</i> , 2015, 15, e237-e241.	2.4	13
511	Cardiovascular Toxicity from Chemotherapy and Anticancer Treatment. , 2015, , 341-361.		0
512	Phase I dose-finding study of the gamma secretase inhibitor PF-03084014 (PF-4014) in combination with docetaxel in patients (pts) with advanced triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 1068-1068.	1.6	4
513	Phase I study of the PI3K/mTOR inhibitor PF-05212384 in combination with other antitumor agents.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2590-2590.	1.6	4
514	Abstract P4-11-15: Risk stratification within luminal B breast cancer using a second generation prognostic RNA signature. , 2015, , .		0
515	ecancermedalscience. <i>Ecancermedalscience</i> , 2014, 8, 472.	1.1	2
516	ecancermedalscience. <i>Ecancermedalscience</i> , 2014, 8, 463.	1.1	26
517	Design of the Ideal Trial with Immunotherapeutics. <i>Annals of Oncology</i> , 2014, 25, iv6.	1.2	0
518	Optimal adjuvant chemotherapy in breast cancer: selection of agents. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 605-611.	3.1	4
519	Successes and Limitations of Targeted Cancer Therapy in Breast Cancer. <i>Progress in Tumor Research</i> , 2014, 41, 15-35.	0.1	34
520	Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets. <i>Pharmaceuticals</i> , 2014, 7, 943-953.	3.8	69
521	Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes. <i>Breast Cancer Research</i> , 2014, 16, R65.	5.0	138
522	Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. <i>Annals of Oncology</i> , 2014, 25, 1979-1987.	1.2	122

#	ARTICLE	IF	CITATIONS
523	“Tu quoque Brute fili mi!” (Julius Caesar, Ides of March, 44 BC). <i>Current Opinion in Oncology</i> , 2014, 26, 543-544.	2.4	0
524	Tumor-stroma crosstalk. <i>Current Opinion in Oncology</i> , 2014, 26, 551-555.	2.4	46
525	Immune Checkpoint Blockade in Cancer Treatment: A Double-Edged Sword Cross-Targeting the Host as an “Innocent Bystander”. <i>Toxins</i> , 2014, 6, 914-933.	3.4	62
526	Expert perspectives on biosimilar monoclonal antibodies in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 233-239.	2.5	48
527	Monitoring tumor-derived cell-free DNA in patients with solid tumors: Clinical perspectives and research opportunities. <i>Cancer Treatment Reviews</i> , 2014, 40, 648-655.	7.7	101
528	Dendritic cell-based vaccines: clinical applications in breast cancer. <i>Immunotherapy</i> , 2014, 6, 349-360.	2.0	38
529	High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer. <i>Breast</i> , 2014, 23, 69-75.	2.2	92
530	A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. <i>European Journal of Cancer</i> , 2014, 50, 277-289.	2.8	212
531	Dinaciclib for the treatment of breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1305-1312.	4.1	42
532	Immune approaches to the treatment of breast cancer, around the corner?. <i>Breast Cancer Research</i> , 2014, 16, 204.	5.0	38
533	Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives. <i>Breast Cancer Research</i> , 2014, 16, 205.	5.0	56
534	No Link between Breast Cancer and Meningioma: Results from a Large Monoinstitutional Retrospective Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 215-217.	2.5	11
535	Reply to L.K. Mell et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 1090-1091.	1.6	0
536	Early-stage lung cancer—what do the experts recommend?. <i>Annals of Oncology</i> , 2014, 25, 1451-1453.	1.2	1
537	Immunoscore breast cancer: TILs remember what they target. <i>Annals of Oncology</i> , 2014, 25, 1455-1456.	1.2	15
538	Investigational platelet-derived growth factor receptor kinase inhibitors in breast cancer therapy. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 599-610.	4.1	13
539	Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. <i>Annals of Oncology</i> , 2014, 25, 611-618.	1.2	359
540	WT1, NY-ESO-1 and Prame Expression in Breast Cancer Subtypes. <i>Annals of Oncology</i> , 2014, 25, 117.	1.2	1

#	ARTICLE	IF	CITATIONS
541	FINESSE: An open, three-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or nonamplified estrogen receptor-positive metastatic breast cancer.. Journal of Clinical Oncology, 2014, 32, TPS1134-TPS1134.	1.6	2
542	Barriers to the use of trastuzumab for HER2+ breast cancer and the potential impact of biosimilars: A physician survey in the United States and emerging markets.. Journal of Clinical Oncology, 2014, 32, 610-610.	1.6	0
543	Abstract 627: Immunogenic cell death as novel immune response mechanism to EGFR-targeted therapy in CRC. Cancer Research, 2014, 74, 627-627.	0.9	1
544	Does immediate breast reconstruction after mastectomy and neoadjuvant chemotherapy influence the outcome of patients with non-endocrine responsive breast cancer?. Anticancer Research, 2014, 34, 6677-83.	1.1	11
545	ecancermedalscience. Ecancermedalscience, 2013, 7, 320.	1.1	23
546	ecancermedalscience. Ecancermedalscience, 2013, 7, 291.	1.1	0
547	ecancermedalscience. Ecancermedalscience, 2013, 7, 299.	1.1	17
548	Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction. European Journal of Surgical Oncology, 2013, 39, 260-265.	1.0	35
549	Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of Oncology, 2013, 24, 2206-2223.	1.2	2,805
550	Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer. Breast, 2013, 22, 650-656.	2.2	70
551	High Ki67 predicts unfavourable outcomes in early breast cancer patients with a clinically clear axilla who do not receive axillary dissection or axillary radiotherapy. European Journal of Cancer, 2013, 49, 3083-3092.	2.8	14
552	Molecular Pathways: Human Leukocyte Antigen G (HLA-G). Clinical Cancer Research, 2013, 19, 5564-5571.	7.0	118
553	Tailoring Adjuvant Treatments for the Individual Patient with Luminal Breast Cancer. Hematology/Oncology Clinics of North America, 2013, 27, 703-714.	2.2	5
554	Obesity increases the incidence of distant metastases in oestrogen receptor-negative human epidermal growth factor receptor 2-positive breast cancer patients. European Journal of Cancer, 2013, 49, 3588-3597.	2.8	57
555	Cytotoxic effect of (1-methyl-1 H -imidazol-2-yl)-methanamine and its derivatives in Pt II complexes on human carcinoma cell lines: A comparative study with cisplatin. Bioorganic and Medicinal Chemistry, 2013, 21, 2379-2386.	3.0	23
556	Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast Cancer. Clinical Cancer Research, 2013, 19, 28-33.	7.0	173
557	Best management of locally advanced inoperable breast cancer. European Journal of Cancer, Supplement, 2013, 11, 289-290.	2.2	3
558	Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncology, The, 2013, 14, 962-970.	10.7	173

#	ARTICLE	IF	CITATIONS
559	Locoregional recurrence in patients with HER2 positive breast cancer. Breast, 2013, 22, 856-862.	2.2	11
560	Developing an effective breast cancer vaccine: Challenges to achieving sterile immunity versus resetting equilibrium. Breast, 2013, 22, S96-S99.	2.2	6
561	Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: A systematic review of randomized controlled trials. Cancer Treatment Reviews, 2013, 39, 44-50.	7.7	71
562	Evaluation of fat grafting safety in patients with intra epithelial neoplasia: a matched-cohort study. Annals of Oncology, 2013, 24, 1479-1484.	1.2	172
563	Immunotherapeutics for breast cancer. Current Opinion in Oncology, 2013, 25, 602-608.	2.4	27
564	HER2 signaling pathway and trastuzumab cardiotoxicity. Future Oncology, 2013, 9, 179-181.	2.4	14
565	Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer. Acta Oncol ³ gica, 2013, 52, 1649-1656.	1.8	56
566	End Points and Trial Design in Geriatric Oncology Research: A Joint European Organisation for Research and Treatment of Cancer ² “Alliance for Clinical Trials in Oncology”International Society of Geriatric Oncology Position Article. Journal of Clinical Oncology, 2013, 31, 3711-3718.	1.6	267
567	Abstract OT2-6-01: Phase 2 study of palbociclib (CDK 4/6 inhibitor) for ER positive, HER2- negative post-menopausal advanced breast cancer patients recurring after hormonal therapy (to reverse) Tj ETQq1 1 0.784314 rgBT /@verlock		
568	Abstract P4-12-11: Patient preference for subcutaneous trastuzumab via handheld syringe versus intravenous infusion in HER2-positive early breast cancer: Cohort 2 of the PrefHer study. , 2013, , .		4
569	Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with breast cancer.. Journal of Clinical Oncology, 2013, 31, 617-617.	1.6	0
570	ALGA: A cancer patient profiling tool to improve physician-patient communication ² “An analysis in breast cancer patients.. Journal of Clinical Oncology, 2013, 31, 9582-9582.	1.6	0
571	Second primary tumors in cancer patients: A retrospective analysis based on institutional tumor registry.. Journal of Clinical Oncology, 2013, 31, 1595-1595.	1.6	0
572	Outcome and clinical ² “biological characteristics of patients with advanced breast cancer undergoing removal of ovarian/pelvic metastases. Annals of Oncology, 2012, 23, 2884-2890.	1.2	2
573	“œThe only thing I know is that I know nothing” 5-fluorouracil in human milk. Annals of Oncology, 2012, 23, 543-544.	1.2	7
574	Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future?. Annals of Oncology, 2012, 23, 547-555.	1.2	43
575	CMF revisited in the 21st century. Annals of Oncology, 2012, 23, 305-311.	1.2	22
576	Locoregional recurrence risk after lipofilling in breast cancer patients. Annals of Oncology, 2012, 23, 582-588.	1.2	203

#	ARTICLE	IF	CITATIONS
577	Risk factors associated with recurrence after nipple-sparing mastectomy for invasive and intraepithelial neoplasia. <i>Annals of Oncology</i> , 2012, 23, 2053-2058.	1.2	101
578	Immunotherapy in Breast Cancer – Towards a New Understanding of Both Tumor and Host. <i>Breast Care</i> , 2012, 7, 258-260.	1.4	1
579	Prognostic Value of Circulating Tumor Cells According to Immunohistochemically Defined Molecular Subtypes in Advanced Breast Cancer. <i>Clinical Breast Cancer</i> , 2012, 12, 340-346.	2.4	46
580	Risk of Locoregional Recurrence in Patients With False-Negative Frozen Section or Close Margins of Retroareolar Specimen in Nipple-Sparing Mastectomy. <i>Annals of Surgical Oncology</i> , 2012, 19, 4117-4123.	1.5	57
581	Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. <i>Annals of Oncology</i> , 2012, 23, vii155-vii166.	1.2	667
582	Oral Metronomic Cyclophosphamide and Methotrexate Plus Fulvestrant in Advanced Breast Cancer Patients: A Mono-Institutional Case-Cohort Report. <i>Breast Journal</i> , 2012, 18, 470-474.	1.0	25
583	New drugs for breast cancer subtypes: Targeting driver pathways to overcome resistance. <i>Cancer Treatment Reviews</i> , 2012, 38, 303-310.	7.7	28
584	Targeting the subtypes of breast cancer: rethinking investigational drugs. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 191-204.	4.1	3
585	Ultrasound-Guided High-Intensity Focused Ultrasound (USgHIFU) Ablation in Pancreatic Metastasis from Renal Cell Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2012, 35, 1258-1261.	2.0	9
586	Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 277-282.	2.5	61
587	Biopsy of liver metastasis for women with breast cancer: Impact on survival. <i>Breast</i> , 2012, 21, 284-288.	2.2	25
588	A meta-analysis of receptor status discordance between primary breast cancer and metastases.. <i>Journal of Clinical Oncology</i> , 2012, 30, 546-546.	1.6	1
589	Immunity and autoimmunity in breast cancer. <i>Breast Cancer Research</i> , 2011, 13, .	5.0	0
590	Multidisciplinary approach in the treatment of patients with small cell bladder carcinoma. <i>European Journal of Surgical Oncology</i> , 2011, 37, 558-562.	1.0	20
591	Should liver metastases of breast cancer be biopsied to improve treatment choice?. <i>Annals of Oncology</i> , 2011, 22, 2227-2233.	1.2	103
592	S19 Immunity and autoimmunity: Revising the concepts of response to cancer. <i>Breast</i> , 2011, 20, S7.	2.2	0
593	Immunity and autoimmunity: revising the concepts of response to breast cancer. <i>Breast</i> , 2011, 20, S71-S74.	2.2	20
594	Autologous fat transplantation in patients with breast cancer: “silencing” or “fueling” cancer recurrence?. <i>Breast</i> , 2011, 20, 351-357.	2.2	137

#	ARTICLE	IF	CITATIONS
595	The management of ductal intraepithelial neoplasia (DIN): open controversies and guidelines of the Istituto Europeo di Oncologia (IEO), Milan, Italy. Breast Cancer Research and Treatment, 2011, 128, 369-378.	2.5	13
596	Intraobserver and interobserver variability in the calculation of apparent diffusion coefficient (ADC) from diffusion-weighted magnetic resonance imaging (DW-MRI) of breast tumours. Radiologia Medica, 2011, 116, 466-476.	7.7	20
597	The Triple-Negative Subtype: New Ideas for the Poorest Prognosis Breast Cancer. Journal of the National Cancer Institute Monographs, 2011, 2011, 108-110.	2.1	48
598	Cancerâ€“testis antigen expression in triple-negative breast cancer. Annals of Oncology, 2011, 22, 98-103.	1.2	81
599	Nipple-sparing mastectomyâ€“is it worth the risk?. Nature Reviews Clinical Oncology, 2011, 8, 742-747.	27.6	51
600	International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). Journal of the National Cancer Institute Monographs, 2011, 2011, 147-151.	2.1	61
601	PD01-02: Randomized Phase II Study of Dasatinib vs Placebo in Addition to Exemestane in Advanced ER/PR-Positive Breast Cancer [BMS CA180-261 Study].. Cancer Research, 2011, 71, PD01-02-PD01-02.	0.9	12
602	First-line therapy with metronomic capecitabine (mC) plus docetaxel (D) followed by mC as maintenance for patients with HER2-negative metastatic breast cancer (MBC): Preliminary analysis of a monocentric phase II trial.. Journal of Clinical Oncology, 2011, 29, e11547-e11547.	1.6	1
603	Prognostic significance of Ki-67 in node-negative (pN0), triple-negative (TN) breast cancer (BC).. Journal of Clinical Oncology, 2011, 29, 1056-1056.	1.6	1
604	Developing an Effective Breast Cancer Vaccine. Cancer Control, 2010, 17, 183-190.	1.8	36
605	Personalizing Medicine Through Personalized Communication: Individuality of the Patient Across Borders and Cultures. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 277-278.	4.9	1
606	High-Intensity Focused Ultrasound Effect in Breast Cancer Nodal Metastasis. CardioVascular and Interventional Radiology, 2010, 33, 447-449.	2.0	8
607	Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer. Breast Cancer Research and Treatment, 2010, 122, 211-217.	2.5	70
608	Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review. Progress in Cardiovascular Diseases, 2010, 53, 94-104.	3.1	146
609	Changes of HER2 Status in Circulating Tumor Cells Compared With the Primary Tumor During Treatment for Advanced Breast Cancer. Clinical Breast Cancer, 2010, 10, 392-397.	2.4	96
610	Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: A mono-institutional case-series report. Breast, 2010, 19, 33-37.	2.2	25
611	Reply to D. Crivellari et al. Journal of Clinical Oncology, 2010, 28, e258-e259.	1.6	2
612	The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. European Journal of Cancer, 2010, 46, 2926-2935.	2.8	149

#	ARTICLE	IF	CITATIONS
613	Abstract P6-12-02: A Randomized Phase II Study of Sunitinib vs. Standard of Care for Patients with Previously Treated Advanced Triple-Negative Breast Cancer. , 2010, , .		6
614	Should liver metastases of breast cancer be biopsied to improve treatment choice?. Journal of Clinical Oncology, 2010, 28, CRA1008-CRA1008.	1.6	17
615	Genetic signature of breast cancer with lymphangitic spread to the chest wall: Results from a randomized phase II study combining bevacizumab with oral vinorelbine plus capecitabine (BEVIX).. Journal of Clinical Oncology, 2010, 28, 1078-1078.	1.6	0
616	Abstract P6-11-14: Long-Term Disease Control with Vinorelbine, Cisplatin and Continuous Infusion of 5-Fluorouracil -ViFuP Regimen-in Metastatic Triple Negative Breast Cancer Patients. , 2010, , .		0
617	Abstract P6-12-06: Oral Vinorelbine and Capecitabine Plus Bevacizumab in Recurrent Inflammatory Breast Cancer: Gene Profiling and Response to Treatment. , 2010, , .		0
618	Clinical Relevance of <i>HER2</i> Overexpression/Amplification in Patients With Small Tumor Size and Node-Negative Breast Cancer. Journal of Clinical Oncology, 2009, 27, 5693-5699.	1.6	235
619	Health-Related Quality of Life in Patients with Hormone Refractory Prostate Cancer Receiving Gefitinib. Urologia Internationalis, 2009, 82, 196-202.	1.3	5
620	Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancer. Annals of Oncology, 2009, 20, 498-502.	1.2	9
621	Cisplatin, Etoposide and Continuous Infusion Bleomycin in Patients with Testicular Germ Cell Tumors: Efficacy and Toxicity Data from a Retrospective Study. Journal of Chemotherapy, 2009, 21, 687-692.	1.5	7
622	Safety, Tolerability and Biological Effects of Long-Term Metronomic Administration of Non-Cytotoxic Anti-Angiogenic Agents. Oncology, 2009, 77, 358-365.	1.9	9
623	Coagulation Disorders in Patients with Cancer: Nontunneled Central Venous Catheter Placement with US Guidance—A Single-Institution Retrospective Analysis. Radiology, 2009, 253, 249-252.	7.3	25
624	Gemcitabine-induced progressive and sustained tumour response in a patient with multi-drug resistant uterine leiomyosarcoma. Ecancermedicalsecience, 2009, 3, 102.	1.1	0
625	QTc prolongation assessment in anticancer drug development: Clinical and methodological issues. Ecancermedicalsecience, 2009, 3, 130.	1.1	11
626	Systemic Therapies for Non-Metastatic Prostate Cancer: Review of the Literature. Onkologie, 2009, 32, 359-363.	0.8	6
627	S15 The (last?) word about biomarkers for angiogenesis. Breast, 2009, 18, S6-S7.	2.2	2
628	S16 Immunizing against breast cancer: A new swing for an old sword. Breast, 2009, 18, S7.	2.2	0
629	Immunizing against breast cancer: A new swing for an old sword. Breast, 2009, 18, S51-S54.	2.2	16
630	Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12—93. Breast Cancer Research and Treatment, 2009, 116, 491-500.	2.5	37

#	ARTICLE	IF	CITATIONS
631	Erlotinib Combined with Cyclosporine in a Liver-Transplant Recipient with Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2009, 4, 138-139.	1.1	6
632	Vinorelbine, cisplatin, and continuous infusion of 5-fluorouracil (ViFuP regimen) in carcinoma of unknown primary. <i>Journal of Clinical Oncology</i> , 2009, 27, e20682-e20682.	1.6	0
633	Daily low-dose aspirin in cancer patients with central venous catheter: new role for an old drug. <i>Supportive Care in Cancer</i> , 2008, 16, 313-314.	2.2	0
634	Dendritic cell sarcoma: An analytic overview of the literature and presentation of original five cases. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 65, 1-7.	4.4	86
635	PHASE I/II STUDY OF THE TUMOUR-TARGETING HUMAN L19- IL2 MONOCLONAL ANTIBODY-CYTOKINE FUSION PROTEIN IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA. <i>European Urology Supplements</i> , 2008, 7, 307.	0.1	0
636	Drug-induced QTc interval prolongation: A proposal towards an efficient and safe anticancer drug development. <i>European Journal of Cancer</i> , 2008, 44, 494-500.	2.8	44
637	Phase I/II study of the tumor-targeting human L19-IL2 monoclonal antibody-cytokine fusion protein in patients with advanced renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 16032-16032.	1.6	1
638	Cancer therapy and the “broken heart”: Decision making during treatment of cancer in patients with left ventricular systolic dysfunction (LVSD). <i>Journal of Clinical Oncology</i> , 2008, 26, 9619-9619.	1.6	0
639	Surrogate markers of antiangiogenic therapy in patients with locally advanced breast cancer with lymphangitic spread to the chest wall: Results from a phase II randomized study of bevacizumab with sequential versus concurrent oral vinorelbine plus capecitabine. <i>Journal of Clinical Oncology</i> , 2008, 26, 14649-14649.	1.6	0
640	Vaccine immunotherapy in breast cancer treatment: promising, but still early. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 1225-1241.	2.4	38
641	Re: Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients with 5-Fluorouracil, Leucovorin, Cisplatin, and Etoposide in a Randomized Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1345-1346.	6.3	4
642	To switch or not to switch: implications of sequencing adjuvant endocrine therapy in patients with breast cancer. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 510-511.	4.3	1
643	Re: Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1210-1210.	6.3	4
644	Erratum to “A proper schedule of weekly paclitaxel and gemcitabine combination is highly active and very well tolerated in NSCLC patients” [Lung cancer 54 (2006) 359-364]. <i>Lung Cancer</i> , 2007, 58, 431.	2.0	0
645	Absence of epidermal growth factor receptor gene mutations in patients with hormone refractory prostate cancer not responding to gefitinib. <i>Prostate</i> , 2007, 67, 603-604.	2.3	17
646	Challenges and prospects of immunotherapy as cancer treatment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2007, 1776, 108-123.	7.4	43
647	Immunology and breast cancer: Therapeutic cancer vaccines. <i>Breast</i> , 2007, 16, 20-26.	2.2	22
648	S12 Immunity and breast cancer cells: Role of vaccination. <i>Breast</i> , 2007, 16, S3-S4.	2.2	0

#	ARTICLE	IF	CITATIONS
649	Low-dose aspirin for the prevention of venous thromboembolism in breast cancer patients treated with infusional chemotherapy after insertion of central vein catheter. <i>Supportive Care in Cancer</i> , 2007, 15, 1213-1217.	2.2	12
650	Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity. <i>Anti-Cancer Drugs</i> , 2007, 18, 949-954.	1.4	12
651	A dose finding pharmacokinetic study of the tumor-targeting human L19-IL2 monoclonal antibody-cytokine fusion protein in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2007, 25, 3057-3057.	1.6	7
652	242: Pharmacogenetics Determinants of Anticancer Activity of Intravesical Gemcitabine in Patients with Superficial Transitional Cell Carcinoma (TCC) of The Bladder. <i>Journal of Urology</i> , 2007, 177, 81-81.	0.4	0
653	A phase I dose escalation safety and pharmacokinetic (PK) study of SSR244738 administered as a one-hour intravenous (IV) infusion every 3 weeks in patients (pt) with refractory solid tumors. <i>Journal of Clinical Oncology</i> , 2007, 25, 2518-2518.	1.6	0
654	Factor V Leiden Mutation in Patients with Breast Cancer with a Central Venous Catheter: Risk of Deep Vein Thrombosis. <i>Supportive Cancer Therapy</i> , 2006, 3, 98-102.	0.3	15
655	A proper schedule of weekly paclitaxel and gemcitabine combination is highly active and very well tolerated in NSCLC patients. <i>Lung Cancer</i> , 2006, 54, 359-364.	2.0	5
656	Breast cancer vaccines: a clinical reality or fairy tale?. <i>Annals of Oncology</i> , 2006, 17, 750-762.	1.2	76
657	A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer. <i>Anti-Cancer Drugs</i> , 2006, 17, 1201-1209.	1.4	11
658	In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. <i>British Journal of Cancer</i> , 2006, 95, 289-297.	6.4	43
659	Life-threatening toxic epidermal necrolysis during voriconazole therapy for invasive aspergillosis after chemotherapy. <i>Annals of Oncology</i> , 2006, 17, 1174-1175.	1.2	18
660	â€œBurned outâ€ phenomenon of the testis in retroperitoneal seminoma. <i>Acta OncolÃ³gica</i> , 2006, 45, 335-336.	1.8	15
661	Reply to Letter to the Editor: â€œToxic epidermal necrolysis in patients with malignanciesâ€, by G. Gravante, G. Esposito, M. Marianetti, D. Delogu, G. Sconocchia & A. Montone (doi:10.1093/annonc/mdl089). <i>Annals of Oncology</i> , 2006, 17, 1601-1602.	1.2	2
662	What is the role of QTc prolongation assessment in new drugs development phase I oncology trials?. <i>Journal of Clinical Oncology</i> , 2006, 24, 2006-2006.	1.6	8
663	Vinorelbine-based chemotherapy in hormone-refractory prostate cancer. <i>Anticancer Research</i> , 2006, 26, 2375-80.	1.1	3
664	Treatment of rectal cancer. <i>New England Journal of Medicine</i> , 2006, 355, 2487; author reply 2487-8.	27.0	0
665	Oral administration of vinorelbine can overcome intractable endovenous-vinorelbine-associated acute tumor pain. <i>Supportive Care in Cancer</i> , 2005, 13, 194-195.	2.2	7
666	Systemic Effects of Surgery: Quantitative Analysis of Circulating Basic Fibroblast Growth Factor (bFGF), Vascular Endothelial Growth Factor (VEGF) and Transforming Growth Factor Beta (TGF-Î²) in Patients with Breast Cancer Who Underwent Limited or Extended Surgery. <i>Breast Cancer Research and Treatment</i> , 2005, 93, 35-40.	2.5	59

#	ARTICLE	IF	CITATIONS
667	Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype. <i>Annals of Oncology</i> , 2005, 16, 1094-1099.	1.2	22
668	Re: Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2005, 97, 461-462.	6.3	3
669	Target-Treatment and Patients' Selection: Can We Still Neglect the Timing of Tissue Collection?. <i>Journal of Clinical Oncology</i> , 2005, 23, 6274-6275.	1.6	2
670	Prophylaxis for Venous Thromboembolism in Cancer Patients With a Central Vein Catheter: New Tones for an Old Song. <i>Journal of Clinical Oncology</i> , 2005, 23, 7243-7244.	1.6	3
671	Immunohistochemical Detection of HER1/HER2 Can Be Considered a Predictive Marker of Gefitinib Activity in Non-Small-Cell Lung Cancer?. <i>Journal of Clinical Oncology</i> , 2005, 23, 921-922.	1.6	5
672	Reply to the article "Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity" by V. R. Rozados et al. (<i>Ann Oncol</i> 2004; 15: 1543-1550): and in humans?. <i>Annals of Oncology</i> , 2005, 16, 673.	1.2	6
673	Trabectedin for Women With Ovarian Carcinoma After Treatment With Platinum and Taxanes Fails. <i>Journal of Clinical Oncology</i> , 2005, 23, 1867-1874.	1.6	163
674	Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. <i>Breast Cancer Research</i> , 2005, 8, R4.	5.0	67
675	Phase I dose-escalation trial of a recombinant HER2 vaccine in patients with Stage II/III HER2+ breast cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 2520-2520.	1.6	8
676	Phase I dose escalation study of SR271425 administered as 24-hour intravenous continuous infusion in patients with refractory solid tumors. <i>Journal of Clinical Oncology</i> , 2005, 23, 3116-3116.	1.6	1
677	Clinical results and impact on circulating endothelial cells (CEC) of treatment with combinations of interferon- α (IF α), thalidomide (T) and celecoxib (C) in patients with solid tumors. <i>Journal of Clinical Oncology</i> , 2005, 23, 3193-3193.	1.6	0
678	Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. <i>Annals of Oncology</i> , 2004, 15, 590-593.	1.2	52
679	Drug-Induced Prolongation of the QT Interval. <i>New England Journal of Medicine</i> , 2004, 350, 2618-2621.	27.0	16
680	Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors. <i>Clinical Cancer Research</i> , 2004, 10, 6622-6628.	7.0	333
681	CDX-2 should be included in the work-up of patients with lung metastases from unknown primary. <i>Annals of Oncology</i> , 2004, 15, 1850.	1.2	1
682	Modulation of Epidermal Growth Factor Receptor Status by Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer Is Rare. <i>Journal of Clinical Oncology</i> , 2004, 22, 4966-4970.	1.6	31
683	Male breast cancer: A special therapeutic problem. Anything new? (Review). <i>International Journal of Oncology</i> , 2004, 24, 663.	3.3	20
684	Breast carcinoma in elderly women. <i>Cancer</i> , 2004, 101, 1302-1310.	4.1	176

#	ARTICLE	IF	CITATIONS
685	Adjuvant Therapy for Very Young Women with Breast Cancer: Response According to Biologic and Endocrine Features. <i>Clinical Breast Cancer</i> , 2004, 5, 125-130.	2.4	15
686	Systemic effects of surgery: Quantitative analysis of circulating basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF- β 2) in patients with breast cancer who underwent limited or extended surgery. <i>Journal of Clinical Oncology</i> , 2004, 22, 672-672.	1.6	1
687	Factor V Leiden mutation in patients with breast cancer and a central venous catheter: Relationship with deep vein thrombosis. <i>Journal of Clinical Oncology</i> , 2004, 22, 8020-8020.	1.6	1
688	Factor V Leiden mutation in patients with breast cancer and a central venous catheter: Relationship with deep vein thrombosis. <i>Journal of Clinical Oncology</i> , 2004, 22, 8020-8020.	1.6	1
689	Systemic effects of surgery: Quantitative analysis of circulating basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF- β 2) in patients with breast cancer who underwent limited or extended surgery. <i>Journal of Clinical Oncology</i> , 2004, 22, 672-672.	1.6	0
690	Male breast cancer: a special therapeutic problem. Anything new? (Review). <i>International Journal of Oncology</i> , 2004, 24, 663-70.	3.3	24
691	Optimization of the schedule of gemcitabine-cisplatin combination as induction regimen for patients with biopsy-proven stage IIIa N2 - stage IIIb non-small-cell lung cancer: a prospective phase-II study. <i>Bulletin Du Cancer</i> , 2004, 91, E273-7.	1.6	0
692	Preoperative chemotherapy is essential for conservative surgery of Askin tumors. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2003, 125, 428-429.	0.8	21
693	Venous thromboembolism and cancer: new issues for an old topic. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 48, 65-80.	4.4	38
694	Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer. <i>Pharmacological Reviews</i> , 2003, 55, 57-103.	16.0	65
695	Impact of limited pulmonary function on the management of resectable lung cancer. <i>Lung Cancer</i> , 2003, 41, 71-79.	2.0	25
696	Preoperative and perioperative chemotherapy with 5-fluorouracil as continuous infusion in operable breast cancer expressing a high proliferation fraction: cytotoxic treatment during the surgical phase. <i>Annals of Oncology</i> , 2003, 14, 1477-1483.	1.2	9
697	Breast and ovarian metastatic localization of signet-ring cell gastric carcinoma. <i>Annals of Oncology</i> , 2003, 14, 803-804.	1.2	18
698	Imatinib administration in two patients with liver metastases from GIST and severe jaundice. <i>British Journal of Cancer</i> , 2003, 89, 1403-1404.	6.4	6
699	Catheter-Related Bloodstream Infections, Part II: Specific Pathogens and Prevention. <i>Cancer Control</i> , 2003, 10, 79-91.	1.8	3
700	Hepatic intra-arterial chemotherapy using a percutaneous catheter in pretreated patients with metastatic colorectal carcinoma. <i>Anticancer Research</i> , 2003, 23, 5023-30.	1.1	6
701	Recognizing features that are dissimilar in male and female breast cancer: expression of p21Waf1 and p27Kip1 using an immunohistochemical assay. <i>Annals of Oncology</i> , 2002, 13, 895-902.	1.2	34
702	Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas. <i>Annals of Oncology</i> , 2002, 13, 161-166.	1.2	20

#	ARTICLE	IF	CITATIONS
703	Postoperative Hyperprolactinemia Could Predict Longer Disease-Free and Overall Survival in Node-Negative Breast Cancer Patients. <i>Oncology</i> , 2002, 63, 370-377.	1.9	7
704	Catheter-Related Bloodstream Infections, Part I: Pathogenesis, Diagnosis, and Management. <i>Cancer Control</i> , 2002, 9, 513-523.	1.8	7
705	Mediastinal lymphadenopathy in a patient with breast cancer. <i>Lancet Oncology</i> , The, 2002, 3, 174.	10.7	2
706	Preoperative Chemotherapy in Non-Small-Cell Lung Cancer: Nothing New in N2 Disease. <i>Journal of Clinical Oncology</i> , 2002, 20, 2603-2604.	1.6	1
707	Intrathecal chemotherapy in carcinomatous meningitis from breast cancer. <i>Anticancer Research</i> , 2002, 22, 3057-9.	1.1	37
708	Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine. <i>Lung Cancer</i> , 2001, 31, 267-270.	2.0	18
709	Bone scan had no role in the staging of 765 consecutive operable T1-T2 breast cancer patients without skeletal symptoms. <i>Annals of Oncology</i> , 2001, 12, 724-725.	1.2	11
710	Progress Report on the Palliative Therapy of 100 Patients with Neoplastic Effusions by Intracavitary Low-Dose Interleukin-2. <i>Oncology</i> , 2001, 60, 308-312.	1.9	19
711	Gemcitabine-induced systemic capillary leak syndrome. <i>Annals of Oncology</i> , 2001, 12, 1651-1652.	1.2	49
712	Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. <i>Annals of Oncology</i> , 2001, 12, 1553-1559.	1.2	35
713	Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients. <i>Anticancer Research</i> , 2001, 21, 585-8.	1.1	15
714	Diagnosis of T1 bladder transitional cell carcinoma by denaturing gradient gel electrophoresis urinalysis. <i>Anticancer Research</i> , 2001, 21, 3015-20.	1.1	2
715	GSTM1, P53 and K-ras molecular detection in resectable non-small cell lung cancer by denaturing gradient gel electrophoresis-bronchoalveolar lavage fluid analysis. <i>Anticancer Research</i> , 2001, 21, 3461-9.	1.1	3
716	Chemotherapy with vinorelbine, cisplatin and continuous infusion of 5-fluorouracil in locally advanced breast cancer: a promising low-toxic regimen. <i>Anticancer Research</i> , 2001, 21, 4135-9.	1.1	7
717	Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. <i>Annals of Oncology</i> , 2000, 11, 1057-1060.	1.2	88
718	ACUTE VULVAR VESTIBULITIS OCCURRING DURING CHEMOTHERAPY WITH CRYPTOPHYCIN ANALOGUE LY355703. <i>Obstetrics and Gynecology</i> , 2000, 95, 1030.	2.4	4
719	Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2000, 11, 821-827.	1.2	26
720	Ifosfamide in the elderly: clinical considerations for a better drug management. <i>Critical Reviews in Oncology/Hematology</i> , 2000, 33, 129-135.	4.4	9

#	ARTICLE	IF	CITATIONS
721	Incidence of venous thromboembolism in breast cancer patients during chemotherapy with vinorelbine, cisplatin, 5-fluorouracil as continuous infusion (ViFuP regimen): Is prophylaxis required?. <i>Annals of Oncology</i> , 2000, 11, 117-118.	1.2	12
722	Acute vulvar vestibulitis occurring during chemotherapy with cryptophycin analogue LYy355703. <i>Obstetrics and Gynecology</i> , 2000, 95, 1030.	2.4	1
723	Detection by denaturant gradient gel electrophoresis of tumor-specific mutations in biopsies and relative bronchoalveolar lavage fluid from resectable non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2000, 6, 2393-400.	7.0	16
724	Evaluation of polycyclic aromatic hydrocarbon-DNA adducts in exfoliated oral cells by an immunohistochemical assay. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 1999, 8, 91-6.	2.5	11
725	Analysis of 4-ABP-DNA adducts and p53 alterations in urinary bladder carcinoma. <i>Anticancer Research</i> , 1999, 19, 4571-6.	1.1	3
726	P-170 Glycoprotein (MDR) and p53 Expression in Breast Cancer. <i>Breast Journal</i> , 1998, 4, 270-276.	1.0	1
727	4-Aminobiphenyl-DNA adducts in laryngeal tissue and smoking habits: an immunohistochemical study. <i>Carcinogenesis</i> , 1998, 19, 353-357.	2.8	25
728	Immunohistochemical analysis of p53 protein in transplant recipients with Kaposi's sarcoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 1997, 123, 240-242.	2.5	8
729	Immunohistochemical analysis of 4-aminobiphenyl-DNA adducts in oral mucosal cells of smokers and nonsmokers. <i>Anticancer Research</i> , 1997, 17, 2827-30.	1.1	20
730	Prognostic significance of cytoplasmic p53 overexpression in colorectal cancer. An immunohistochemical analysis. <i>European Journal of Cancer</i> , 1996, 32, 802-806.	2.8	55
731	Detection of oncogene mutation from neoplastic colonic cells exfoliated in feces. <i>Diseases of the Colon and Rectum</i> , 1996, 39, 1238-1244.	1.3	40
732	Immunohistochemical quantitation of 4-aminobiphenyl-DNA adducts and p53 nuclear overexpression in T1 bladder cancer of smokers and nonsmokers. <i>Carcinogenesis</i> , 1996, 17, 911-916.	2.8	61
733	Targeting HER2 in breast cancer: new drugs and paradigms on the horizon. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , .	0.8	1
734	The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046. <i>Investigational New Drugs</i> , 0, , .	2.6	8
735	Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 0, , .	7.1	51